
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6). Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 7/1/26**
(See policy history boxes for previous effective dates)

Title: Vagus Nerve Stimulation

Description

Stimulation of the vagus nerve can be performed using a pulsed electrical stimulator implanted within the carotid artery sheath. This technique has been proposed as a treatment for refractory seizures, depression, and other disorders. There are also devices available that are implanted at different areas of the vagus nerve. This evidence review also addresses devices that stimulate the vagus nerve transcutaneously.

Medical Policy Statement

Implantable vagus nerve stimulators that are FDA approved are **established** when criteria are met.

Transcutaneous (non-implanted) vagus nerve stimulators are **experimental/investigational**. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

Integrated vagus nerve neurostimulation systems are **experimental/investigational**. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

Inclusionary and Exclusionary Guidelines

Inclusions:

- Seizures that are refractory to medical treatment*
*Medically refractory seizures are defined as seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels of antiepileptic drugs because of intolerable adverse events of these drugs.

Exclusions:

- Other conditions including but not limited to:
 - Depression
 - Heart failure
 - Upper-limb impairment due to stroke
 - Essential tremor
 - Headaches (cluster headaches, migraines, etc.)
 - Fibromyalgia
 - Tinnitus
 - Traumatic brain injury
 - Autism
 - Schizophrenia
 - Rheumatoid arthritis
 - Transcutaneous (nonimplantable) vagus nerve stimulation devices all indications.
 - Integrated vagus nerve neurostimulation systems for all indications.
-

CPT/HCPCS Level II Codes

Established codes:

61885	61886	61889	61891	61892	
64553	64568	64569	64570		
95970	95976	95977	L8680	L8681	L8682
L8683	L8685	L8686	L8687	L8688	
L8689					

Other codes (investigational, not medically necessary, etc.):

E0770	E0735			
0908T*	0909T*	0910T*	0911T*	0912T*
C1827				

Notes: *The implantation, replacement, removal, analysis and programming of integrated vagus nerve neurostimulation systems is represented by codes 0908T, 0909T, 0910T, 0911T, and 0912T. Currently there are no FDA approved integrated neurostimulation systems.

- Code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at BCBSM or BCN to verify coverage.

- *Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.*
-

Background

Vagus Nerve Stimulation

Vagus nerve stimulation (VNS) was initially investigated as a treatment alternative in patients with medically refractory partial-onset seizures for whom surgery is not recommended or for whom surgery has failed. Over time, the use of VNS has expanded to generalized seizures, and it has been investigated for a range of other conditions.

While the mechanisms for the therapeutic effects of VNS are not fully understood, the basic premise of VNS in the treatment of various conditions is that vagal visceral afferents have a diffuse central nervous system projection, and activation of these pathways has a widespread effect on neuronal excitability. An electrical stimulus is applied to axons of the vagus nerve, which have their cell bodies in the nodose and junctional ganglia and synapse on the nucleus of the solitary tract in the brainstem. From the solitary tract nucleus, vagal afferent pathways project to multiple areas of the brain. Vagus nerve stimulation may also stimulate vagal efferent pathways that innervate the heart, vocal cords, and other laryngeal and pharyngeal muscles, and provide parasympathetic innervation to the gastrointestinal tract.

Other types of implantable vagus nerve stimulators that are placed in contact with the trunks of the vagus nerve at the gastroesophageal junction are not addressed in this evidence review.

Stimulation of the vagus nerve can be performed using implantable, transcutaneous, or integrated nerve stimulation devices. The implantable device consists of coil electrodes at the end of a lead wire that are wrapped around the vagus nerve within the carotid artery sheath inserted through an incision in the neck. The lead wire is then guided down to the chest and connected to a battery that is placed into a pocket under the skin in the upper chest. This technique has been proposed as a treatment for refractory seizures, depression, and other disorders. There are also devices available that are implanted at different areas of the vagus nerve. This evidence review also addresses devices that stimulate the vagus nerve transcutaneously. This method involves the application of electrical currents through non-invasive surface electrodes at select locations, most commonly targeting the auricular branch of the vagus nerve at the external ear and the cervical branch of the vagus nerve in the neck. The integrated neurostimulation device is a self-contained nerve stimulator that generates electrical pulses using an integrated circuit, telemetry hardware and a rechargeable battery enclosed in a case. The vagus nerve is exposed via open incision, and a silicon position device is placed under the nerve and closes around the nerve. The integrated nerve stimulation device is then placed into positioning device and the incision is closed. The nerve stimulation is set through an iPad application and the patients recharge the device using a wireless charger.

Summary of Evidence

Vagus Nerve Stimulation

For individuals who have seizures refractory to medical treatment who receive vagus nerve stimulation (VNS), the evidence includes randomized controlled trials RCTs and multiple observational studies. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs have reported significant reductions in seizure frequency for patients with partial-onset seizures. The uncontrolled studies have consistently reported large reductions in a broader range of seizure types in both adults and children. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have treatment-resistant depression who receive VNS, the evidence includes 3 RCTs evaluating the efficacy of implanted VNS for treatment-resistant depression compared to sham, 1 RCT comparing therapeutic to low-dose implanted VNS, nonrandomized comparative studies, and case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Two sham-controlled RCTs only reported short-term results and found no significant improvement in the primary outcome. One sham-controlled trial with follow-up through 12 months found no difference in Montgomery-Åsberg Depression Rating Scale (MADRS) time in response between active and sham groups; however, several clinician and self-reported measures of symptom improvement showed a benefit for VNS. The low-dose VNS controlled trial reported no statistically significant differences between the dose groups for change in depression symptom score from baseline. Other available studies are limited by small sample sizes, potential selection and confounding biases, and lack of a control group in the case series studies. The evidence is insufficient to determine that the technology results in an improvement in on the net health outcome.

For individuals who have chronic heart failure who receive VNS, the evidence includes a systematic review including 4 RCTs and case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Meta-analyses of the RCTs evaluating chronic heart failure found significant improvements in New York Heart Association functional class, quality of life, 6-minute walk-test, and N-terminal-pro brain natriuretic peptide levels in patients treated with VNS compared to control. An analysis of the ANTHEM-HF uncontrolled trial evaluated longer-term outcomes of VNS use in chronic heart failure. They found that left ventricular (LV) ejection fraction improved by 18.7%, 19.3%, and 34.4% at 12, 24, and 36 months, respectively, with high-intensity VNS. Individuals with low-intensity VNS only had significant improvement in LV ejection fraction at 24 months (12.3%). The ANTHEM-HFpEF trial found improvements in New York Heart Association functional class, quality of life, and 6-minute walk test distances in patients with preserved ejection fraction and implanted VNS. Although this data is promising, a lack of a no-VNS comparator group precludes drawing conclusions based on findings from the uncontrolled studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have upper-limb impairment due to stroke who receive VNS, the evidence includes 3 pilot RCTs, a post hoc analysis of one of the RTC's, a systematic review of the 3 RCTs, a systematic review and meta-analysis, and a case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Two RCTs compared VNS plus rehabilitation to rehabilitation alone, 1 failed to show significant improvements for the VNS group on response and function outcomes, but the other, which had a larger patient population, found a significant difference in response and function outcomes. The other RCT compared VNS to sham and found that although VNS significantly improved response rate, there were 3 serious adverse events related to surgery. A systematic review pooling these

data found that implanted VNS improved upper limb motor function based on Fugl-Meyer Assessment-Upper Extremity score when compared to control. The case series showed that VNS paired with rehabilitation therapy in patients with chronic ischemic stroke resulted in meaningful functional improvements however, there were several limitations in this case series. Overall, longer-term follow-up studies with larger size are needed to evaluate long-term efficacy and safety. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For adults with moderate-to-severe rheumatoid arthritis who receive VNS, the evidence includes 1 pilot randomized, sham-controlled trial and 1 multicenter sham-controlled RCT. The pilot RCT in multidrug-refractory RA demonstrated procedural feasibility and safety. The trial reported that American College of Rheumatology Score 20 [ACR20] and Disease Activity Score-28 [DAS28] outcomes were numerically superior for the VNS group; however, these differences were not statistically compared, as the study wasn't powered for effectiveness. The pivotal RESET-RA trial was a multicenter, double-blind, sham-controlled RCT with a 12-week blinded period; published peer-reviewed results show a high rate of implant success and low rates of adverse events, but do not report additional outcomes. The manufacturer's IFU reports statistical superiority of implantable VNS over sham for the prespecified primary responder endpoint, ACR20, but no significant differences in secondary clinical and functional outcomes (DAS28, The Clinical Disease Activity Index [CDAI], and Health Assessment Questionnaire Disability Index [HAQ-DI]). Safety across studies was acceptable, with mostly mild stimulation-related events and infrequent surgery-related complications. Evidence for implantable VNS remains limited to a small feasibility RCT that was not powered for efficacy, as well as a single pivotal, sham-controlled trial with outcome assessment only available in manufacturer documents, which has not yet been peer-reviewed. Overall, the certainty of evidence for RA remains limited, and an additional large, peer-reviewed RCT with longer blinded follow-up is warranted. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have other neurologic conditions (e.g., essential tremor, headache, fibromyalgia, tinnitus, autism) who receive VNS, the evidence includes case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Case series are insufficient to make conclusions regarding efficacy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Transcutaneous Vagus Nerve Stimulation

For individuals with cluster headaches who receive transcutaneous VNS (tVNS; also referred to as noninvasive VNS [nVNS]) to prevent cluster headaches, the evidence includes 1 RCT and 1 systematic review. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. One RCT for prevention of cluster headaches showed a reduction in headache frequency but did not include a sham treatment group. The systematic review evaluating the same RCT found that nVNS reduced the frequency of weekly attacks and improved response rates in preventive cluster headache, however the certainty of evidence rated as low. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with cluster headaches who receive nVNS to treat acute cluster headache, the evidence includes RCTs and 1 systematic review. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. The ACT1 and ACT2 RCTs compared nVNS to sham for treatment of acute cluster headache in patients including both

chronic and episodic cluster headache. In ACT1, there was no statistically significant difference in the overall population in the proportion of patients with pain score of 0 or 1 at 15 minutes into the first attack and no difference in the proportion of patients who were pain-free at 15 minutes in 50% or more of the attacks. In the episodic cluster headache subgroup (n=85) both outcomes were statistically significant favoring nVNS although the interaction p-value was not reported. In ACT2, the proportion of attacks with pain intensity score of 0 or 1 at 30 minutes was higher for nVNS in the overall population (43% versus 28%, $p=.05$) while the proportion of attacks that were pain-free at 15 minutes was similar in the two treatment groups in the overall population (14% vs 12%). However, a statistically significantly higher proportion of attacks in the episodic subgroup (n=27) were pain-free at 15 minutes in the nVNS group compared to sham (48% vs 6%, $p<.01$). These studies suggest that people with episodic and chronic cluster headaches may respond differently to acute treatment with nVNS. Studies designed to focus on episodic cluster headache are needed. Quality of life and functional outcomes have not been reported. Treatment periods ranged from only 2 weeks to 1 month with extended open-label follow-up of up to 3 months. There are few adverse events of nVNS and they are mild and transient. The systematic review evaluating the same RCTs found that nVNS did not improve pain freedom, pain relief, or attack duration compared to controls, with certainty of evidence rated low to very low. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with migraine headache who receive nVNS to treat acute migraine headache, the evidence includes 1 RCT and 1 systematic review. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. One RCT has evaluated nVNS for acute treatment of migraine with nVNS in 248 patients with episodic migraine with/without aura. There was not a statistically significant difference in the primary outcome of the proportion of participants who were pain-free without using rescue medication at 120 minutes (30% vs 20%; $p=.07$). However, the nVNS group had a higher proportion of patients with decrease in pain from moderate or severe to mild or no pain at 120 minutes (41% vs 28%; $p=.03$) and a higher proportion of patients who were pain-free at 120 for 50% or more of their attacks (32% vs 18%; $p=.02$). There are few adverse events of nVNS and they are mild and transient. Quality of life and functional outcomes were not reported and the double-blind treatment period was 4 weeks with an additional 4 weeks of open-label treatment. A systematic review evaluating the same RCT found that nVNS reduced short-term pain but provided no sustained benefit for pain freedom relative to control participants, with the certainty of evidence rated as moderate to low. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with chronic migraine headache who receive nVNS to prevent migraine headache, the evidence includes 3 RCTs and 1 systematic review. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. The EVENT RCT was a feasibility study of prevention of migraine that was not powered to detect differences in efficacy outcomes. It does not demonstrate the efficacy of nVNS for prevention of migraine. The PREMIUM RCT was a phase 3, multicenter, sham-controlled RCT including 341 randomized participants with a 12-week double-blind treatment period. The results of PREMIUM demonstrated that nVNS was not statistically significantly superior to sham with respect to the outcomes of reduction of at least 50% in migraine days from baseline to the last 4 weeks, reduction in number of migraine days from baseline to the last 4 weeks or acute medication days. The PREMIUM II trial was a multicenter, sham-controlled RCT including 231 randomized participants with a 12-week double-blind treatment period. The trial was terminated early due to the COVID-19 pandemic and results were based on a modified

intention-to-treat population that included 113 total participants. Results demonstrated that treatment with nVNS was not statistically significantly superior to sham with respect to the primary outcome of reduction in the number of migraine days per month during weeks 9 through 12, nor other outcomes such as mean change in the number of headache days or acute medication days. However, the percentage of individuals with at least a 50% reduction in the number of migraine days was significantly greater in the nVNS group than in the sham group. The systematic review found that nVNS resulted in only small reductions in monthly migraine or headache days compared with sham, and the results did not consistently achieve statistical significance. The certainty of evidence for preventive migraine was judged low to very low. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have other neurologic, psychiatric, or metabolic disorders (e.g., epilepsy, depression, schizophrenia, noncluster headache, impaired glucose tolerance, fibromyalgia, stroke) who receive tVNS, the evidence includes RCTs, systematic reviews of these RCTs and case series for some of the conditions. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs are all small and have various methodologic problems. None showed definitive efficacy of tVNS in improving patient outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms. The following is a summary of the key literature to date.

TREATMENT-RESISTANT SEIZURES

REVIEW OF EVIDENCE

Systematic Reviews

Reports on the use of VNS to treat medication-resistant seizure disorders date to the 1990s and were coincident with preapproval and early post approval study of the device.

Characteristics of systematic reviews are shown in Table 1. Results are shown in Tables 2 and 3.

Panebianco et al (2015) updated a Cochrane systematic review and meta-analysis of VNS to treat partial seizures.¹ Reviewers specifically evaluated randomized, double-blind, parallel or crossover, controlled trials of VNS as add-on treatment comparing high- and low-stimulation paradigms plus VNS stimulation with no stimulation or a different intervention. Five trials (N=439) compared high-frequency stimulation with low-frequency stimulation in participants ages 12 to 60 years, and another trial compared high-frequency stimulation with low-frequency stimulation in children. Results are shown in Table 2. Risk of bias was rated as low for most

domains across studies. However, none of the protocols for the included studies were available and therefore were rated as having an unclear risk of bias for selective reporting. In addition, all studies were sponsored by the manufacturers of the device. An updated Cochrane systematic review published in 2022 by the same author group did not identify any new RCTs.²

Table 1. Characteristics of Systematic Reviews of Implantable VNS for Epilepsy

Study	Dates	Studies	Participants	N (Range)	Design	Duration
Panebianco et al (2015,2022) ^{1,2}	Up to March 2022	5	Adults or children with drug-resistant partial seizures not eligible for surgery or who failed surgery	439 (22 to 198)	RCT	12 to 20 weeks
Englot et al (2011) ³	Up to 2010	15	Adults or children with medically refractory epilepsy	955 (16 to 196)	RCT or prospective observational study	3 months to 5 years

RCT: randomized clinical trial; VNS: vagus nerve stimulator

Table 2. Results of Systematic Reviews of RCTs of Implantable VNS for Epilepsy

Study	50% or Greater Reduction in Seizure Frequency	VNS Treatment Withdrawal	Voice Alteration or Cough	Cough	Dyspnea
Panebianco et al. (2015) ¹					
Total N	373	375	334	334	312
Pooled effect (95% CI)	1.73 (1.13 to 2.64)	2.56 (0.51 to 12.71)	2.17 (1.49 to 3.17)	1.09 (0.74 to 1.62)	2.45 (1.07 to 5.60)
I ² (p ^a)	18% (p=.30)	0% (p=.74)	32% (p=.23)	0% (p=.54)	0% (p=.77)

CI: confidence interval; RCT: randomized controlled trial; VNS: vagus nerve stimulator

^a p for heterogeneity

Englot et al (2011) conducted a systematic review of the literature through November 2010 assessing the efficacy of VNS and its predictors of response.³ Fifteen RCTs and prospective observational studies were included. Analyses combined different study types. Given that the meta-analysis of RCTs is described in the Cochrane review, the observational studies only from the Englot review are shown in Table 3.

Table 3. Summary of Prospective Studies Included in Systematic Review

Study (year)	N	Duration of FU	No. of sites	Seizure Type	Seizure Frequency Reduction >50%, %
Ben-Menachem et al (1999) ⁴	64	3-64 mo	Single	Mixed	45
Parker et al (1999) ⁵	15 ^a	1 y	Single	Mixed	27
Labar et al (1999) ⁶	24	3 mo	Single	Generalized	46
DeGiorgio et al (2000) ⁷	195	12 mo	Multisite	Mixed	35
Chavel et al (2003) ⁸	29	1-2 y	Single	Partial	54 ^b
Vonck et al (1999 ⁹ ; 2004 ¹⁰)	118	> 6 mo	Multisite	Mixed	50

Majoie et al (2001 ¹¹ ; 2005 ¹²)	19 ^a	2 y	Single	Mixed	21
Huf et al (2005) ¹³	40 ^c	2 y	Single	NR	28
Kang et al (2006) ¹⁴	16 ^d	>1 y	Multisite	Mixed	50
Ardesch et al (2007) ¹⁵	19	>2 y	Single	Partial	33 ^e

Adapted from Englot et al (2011).³

FU: follow-up; NR: not reported;

a Children with encephalopathy. b Rate at 1-year follow-up. c Adults with low IQ. d Children. e Rate at 2 years.

Randomized Controlled Trials

As noted in the previous section, 5 RCTs (N=439) have evaluated VNS. Four trials compared high frequency VNS that was thought to be therapeutic versus low frequency VNS at levels that were thought to be sub-therapeutic. One trial compared rapid versus medium versus slow cycle VNS. Characteristics of the trials are shown in Table 4. Results are shown in Table 5.

Table 4. Characteristics of Double-Blind RCTs of VNS for Epilepsy

Study	Dates	Participants	Interventions	
			Active	Comparator
Michael (1993) ¹⁶	NR	Patients with refractory partial seizures (race or ethnicity not reported)	n=10 High stimulation	n = 12 Low stimulation
Ben-Menchem/VNS Study Group (1994, 1995) ^{17,4}	~1991	Patients with refractory partial (simple or complex) seizures Mean age, 35 years (range 14 to 57) (race or ethnicity not reported)	n=54 High stimulation	n=60 Low stimulation
Handforth et al (1998) ¹⁸	1995 to 1996	Patients with 6+ partial-onset seizures over 30 days including complex partial or secondarily generalized seizures (86.4% white, 8.6% Hispanic/Latino, 5% race/ethnicity not reported)	n=95 High stimulation	n=103 Low stimulation
DeGiorgio et al (2005) ⁷	NR	Patients ages 12 years and older, 1 or more antiepileptic medications and at least 1 seizure/30 days with alteration of consciousness (race or ethnicity not reported)	n=19 Rapid cycle n=19 Med cycle	n=23 Slow cycle
Klinkenberg et al (2012) ¹⁹	NR	Children with medically refractory epilepsy not eligible for epilepsy surgery (race or ethnicity not reported)	n=21 High output	n=20 Low output

NR: not reported; RCT: randomized controlled trial; VNS: vagus nerve stimulation.

The trials generally included people with drug resistant partial epilepsy with VNS as an add-on treatment. The blinded treatment phase ranged from 12 to 20 weeks in the 5 trials. Four trials reported the outcome of response (50% or greater reduction in seizure frequency) and the risk ratio for ranged from 1.49 to 8.27 in the 3 trials that favored high frequency VNS; the risk ratio was statistically significantly different from the null in 1 trial. One trial reported a risk ratio that did not favor high frequency VNS for the response outcome but was not statistically significant.

Table 5. Results of Double-Blind RCTs of VNS for Epilepsy

Study	50% or Greater Reduction in Seizure Frequency (%)	Change in Seizure Frequency	Quality of life	Functional Outcomes
Michael (1993) ¹⁶				
N	22	NR	NR	NR
High stimulation	30%			
Low stimulation	0%			
Treatment effect (95% CI)	RR=8.27 (0.48 to 143.35)			

Ben-Menchem/VNS Study Group (1994, 1995) ^{17,4}				
N	114	67	NR	NR
High stimulation	31%	-31%		
Low stimulation	13%	-11%		
Treatment effect (95% CI)	RR=2.36 (1.11 to 5.03)	Difference=-20% (NR); p=.03		
Handforth et al (1998) ¹⁷			Global evaluation scores of patient well-being with visual analog scale by blinded interviewer at visits 7-9, mean	
N	196	196	NR	
High stimulation	23%	-28%	NR	
Low stimulation	16%	-15%	NR	
Treatment effect (95% CI)	RR=1.49 (0.84 to 2.66)	p=.04	Difference=4.0 mm (0.6 to 7.4); p=.02	
DeGiorgio et al (2005) ⁷		Median % reduction at 3 months		
N	42	NR	NR	NR
Rapid cycle	32%	-26%		
Slow cycle	26%	-29%		
Treatment effect (95% CI)	NR	NR		
Klinkenberg et al (2012) ¹⁹				
N	41	41	NR	NR
High stimulation	14%	+23%		
Low stimulation	20%	-9%		
Treatment effect (95% CI)	RR=0.71 (0.18 to 2.80)	p=.61		

CI: confidence interval; NR: not reported; RR: risk ratio; VNS: vagus nerve stimulation

Ryvlin et al (2014) reported on an RCT on long-term quality of life outcomes for 112 patients with medication-resistant focal seizures, which supported the beneficial effects of VNS for this group.²⁰

Observational Studies

Resective surgery is a less attractive therapeutic option for individuals with generalized treatment-resistant seizures that may be multifocal or involve an eloquent area. VNS has been evaluated as an alternative to disconnection procedures such as surgical division of the corpus callosum. The evidence for the efficacy of VNS for generalized seizures in adults is primarily from observational data, including registries and small cohort studies. Englot et al (2016) examined freedom from seizure rates and predictors across 5554 patients enrolled in the VNS Therapy Patient Outcomes Registry.²¹ The registry was established in 1999, after the 1997 U.S. Food and Drug Administration approval of VNS, and is maintained by the manufacturer of the device, Cyberonics. Data were prospectively collected by 1285 prescribing physicians from 978 centers (911 in the United States and Canada and 67 internationally) at patients' preoperative baselines and various intervals during therapy. During active data collection, participation in the registry included approximately 18% of all implanted VNS devices. The database was queried in January 2015, and all seizure outcomes reported with the 0- to 4-, 4- to 12-, 12- to 24-, and 24- to 48-month time ranges after VNS device implantation were extracted and compared with patient preoperative baseline. Available information was tracked at each time point of data submission for the following outcomes: patient demographics,

epilepsy etiology and syndrome, historical seizure types and frequencies, quality of life, physician global assessment, current antiepileptic drugs, medication changes, malfunctions, battery changes, and changes in therapy. At each observation point, responders were defined as having a 50% or greater decrease in seizure frequency compared with baseline and nonresponders as less than a 50% decrease. A localized epilepsy syndrome such as partial-onset seizures was recorded in 59% of the registry participants, generalized epilepsy in 27%, and 11% had a syndromic etiology (e.g., Lennox-Gastaut). The outcomes for the approximately 1500 registry enrollees with generalized seizures are summarized in Table 6. These rates did not differ statistically from participants with predominantly partial seizures.

Table 6. Summary of VNS Registry Outcomes

Generalized Seizures	Responder Rate, % ^a	Seizure Freedom Rate, %
0 to 4 mo	50	7
4 to 12 mo	55	8
12 to 24 mo	55	8
24 to 48 mo	≈60 ^b	≈9 ^a

VNS: vagus nerve stimulation.

^a Responder rate: ≥50% decrease in seizure frequency.

^b Approximation based on publication Figure 1 and narrative

Garcia-Navarrete et al (2013) evaluated outcomes after 18 months of follow-up for a prospective cohort of 43 patients with medication-resistant epilepsy who underwent VNS implantation.²² Subjects' seizure types were heterogeneous, but 52% had generalized epilepsy. Pharmacotherapy was unchanged during the study. Twenty-seven (63%) subjects were described as “responders,” defined as having a 50% or greater reduction in seizure frequency compared with the year before VNS implantation. The difference in reduction of seizure frequency was not statistically significant between subjects with generalized and focal epilepsy.

The evidence for VNS for pediatric seizures consists of a variety of small noncomparator trials, prospective observational studies, and retrospective case series. As in the adult studies, there is heterogeneity of seizure etiologies: mixed, syndromic, and idiopathic; there is also generalized and limited information on concomitant antiepileptic drug requirement. Some studies have defined pediatric patients as less than 12 years of age and others have defined them as less than 18 years and may have included patients as young as 2 to 3 years of age. Study subpopulations may have had prior failed resective surgery. Complete freedom from seizures is the exception, and the primary reported end point is 50% or more reduction in seizure frequency, determined over varying lengths of follow-up. There is an overlap of authors for multiple studies suggesting utilization of VNS in specialized clinical care environments. Multiple studies have some form of innovator device company sponsorship.

Table 7 summarizes the evaluable literature on VNS in pediatric populations of all seizure types.

Table 7. Summary of VNS Pediatric Studies

Author (Year)	Study Type	Sample	Seizure Disorder Type	Duration of FU	SFR ≥50% or Median Reduction, n (%) ^a	Notes
Hornig et al 1997) ²³	Case series	19	Mixed	2-30 mo	10 (53)	Prior failed resective surgery: n=3
Murphy et al (1999) ²⁴	Prospective OBS	60	Mixed	18 mo	46 (42) ^a	Age: 26% <12 y

Patwardhan et al (2000) ²⁵	Case series	38	Mixed	12 mo (median)	26 (68)	Age: 11 mo to 16 y
Frost et al (2001) ²⁶	Retrospective case review	50	LGS	6 mo	50 (57.9) ^a	Age: 13 y (median)
You et al (2007) ²⁷	Prospective OBS	28	Mixed	31.4 mo (mean)	15 (53.6)	Age range: 2-17 y
Klinkenberg et al (2012) ¹⁹	RCT ^b	41	Mixed	19 wk	High-stim: 3/21(14.2) Low-stim: 4/20 (20)	Age range: 3-17 y
Cukiert et al (2013) ²⁸	Case series	24	LGS	24 mo	NR ^c	Age: <12 y
Healy et al (2013) ²⁹	Retrospective case review	16	Unknown	3-y review	9 (56)	Age: <12 y
Terra et al (2014) ³⁰	Retrospective case-control ^d	36	Mixed	3-y review	VNS group: 20 (55.4)	Age: <18 y Difference from baseline seizure frequency ^e
Yu et al (2014) ³¹	Retrospective case review	69/252 ^f	Mixed	12 mo	28 (40.6)	Age: <12 y=28
Maleknia et al (2023) ³²	Retrospective cohort study	45	Generalized MRE	5-y	4 (36.4) patients younger than 4 y at 6-mo, 1-, 2-, and 5-y FU 11 (32.4) patients 4 to 6 y at 6-mo; 14 (41.2) patients 4 to 6 y at 1-y; 13 (38.2) patients 4 to 6 y at 2-y; and 14 (41.2) patients 4 to 6 y at 5-y	Age: <6 y (11 patients younger than 4 y)

FU: follow-up; LGS: Lennox-Gastaut syndrome; MRE: medically refractory epilepsy;

NR: not reported; OBS: observational; RCT: randomized controlled trial; SD: standard deviation; SFR: seizure f

a Median reduction in total seizure frequency.

b RCT comparing high- (n=21) with low-stimulation (n=20) VNS.

c Seizure reduction not reported but 10 (41.6%) experienced transient seizure frequency worsening.

d Age-matched 31 VNS with 72 non-VNS controls.

e Baseline seizure frequency; VNS: 346.64 (SD=134.11) versus control group: 83.63 (SD=41.43).

f Sixty-nine of 252 of identified cases had evaluable pre- and postimplantation data.

Section Summary: Treatment-Resistant Seizures

The evidence on the efficacy of VNS for treatment of medically refractory seizures consists of RCTs, meta-analyses, and numerous uncontrolled studies. RCTs and meta-analyses of RCTs have reported a significant reduction in seizure frequency with VNS for patients with partial-onset seizures. The uncontrolled studies and case series have consistently reported reductions of clinical significance, defined as a 50% or more reduction in seizure frequency in both adults and children over almost 2 decades of publications. Interpretation of all outcomes and results were limited by the variety of comparators (when used), variability in length of follow-up, limited published data on antiepileptic medication requirements, mixed seizure etiologies, and history of prior failed resective surgery. There is an overlap of authors across multiple studies, suggesting utilization of VNS in specialized clinical care environments. Multiple studies have some form of innovator device company sponsorship.

TREATMENT-RESISTANT DEPRESSION

Review of Evidence

Systematic Reviews

Several systematic reviews and meta-analyses have assessed the role of VNS in treatment-resistant depression. A 2008 systematic review of the literature for VNS of treatment-resistant depression identified 1 randomized trial.³³ VNS was found to be associated with a reduction in depressive symptoms in the open-label studies. However, results from the only double-blind trial were considered inconclusive.^{34,35} Daban et al (2008) concluded that further clinical trials are needed to confirm efficacy of VNS in treatment-resistant depression.³³

In a meta-analysis that included 14 studies, Martin and Martin-Sanchez (2012) reported that, among the uncontrolled studies included in their analysis, 31.8% of subjects responded to VNS treatment.³⁶ However, results from a meta-regression to predict each study's effect size suggested that 84% of the observed variation across studies was explained by baseline depression severity. Berry et al (2013)³⁷ reported on results from a meta-analysis of 6 industry-sponsored studies of safety and efficacy for VNS in treatment-resistant depression, which included the D-01, D-02, D-03 (Bajbouj et al [2010])³⁸, D-04, and D-21 (Aaronson et al [2013])³⁹ study results. Also, the meta-analysis used data from a registry of patients with treatment-resistant depression (335 patients receiving VNS plus treatment as usual and 301 patients receiving treatment as usual only) that were unpublished at the time of the metaanalysis publication (NCT00320372). The authors reported that adjunctive VNS was associated with a greater likelihood of treatment response (odds ratio [OR], 3.19; 95% confidence interval [CI], 2.12 to 4.66). However, the meta-analysis did not have systematic study selection criteria, limiting the conclusions that can be drawn from it.

Bottomley et al (2020) reported results of a systematic review and meta-analysis of 2 RCTs (Rush et al [2005] and Aaronson et al [2013]), 16 single-arm and 4 nonrandomized comparative studies.⁴⁰ The meta-analysis calculated overall pooled effect estimates for VNS and treatment-as-usual groups, respectively, but did not perform quantitative analysis of comparative treatment effects. Thus, this meta-analysis provides insufficient evidence to permit comparisons between VNS and the control groups.

Randomized controlled trials

Rush et al (2005) reported results of a 10-week, blinded RCT comparing adjunctive VNS with sham (implanted but inactivated VNS) in 235 outpatients with nonpsychotic major depressive disorder or nonpsychotic, depressed phase, bipolar disorder (D-02).³⁴ The patients were treatment-resistant, defined as those who had not responded adequately to between 2 and 6 research-qualified medication trials for the current episode of depression. The primary outcome was response rates (50% or more reduction from baseline on the Hamilton Rating Scale for Depression). There was not a statistically significant difference in response rates at 10 weeks in VNS versus sham (15% versus 10%; $p=.25$). The IDS Systems Review score was considered a secondary outcome and showed a difference that was statistically significant in favor of VNS (17.4%) compared with sham treatment (7.5%; $p=.04$).

Aaronson et al (2013) reported on results from an active-controlled trial in which 331 patients with a history of chronic or recurrent bipolar disorder or major depressive disorder, with a current diagnosis of a major depressive episode, were randomized to 1 of 3 VNS current doses (high, medium, low).³⁹ Patients had a history of failure to respond to at least 4 adequate dose/duration of antidepressant treatment trials from at least 2 different treatment categories. After 22 weeks, the current dose could be adjusted in any of the groups. At follow-up visits at weeks 10, 14, 18, and 22 after enrollment, there were no statistically significant differences between the dose groups for the study's primary outcome, change in IDS score from baseline.

However, mean IDS scores improved significantly for each group from baseline to the 22-week follow-up. At 50-week follow-up, there were no significant differences between the treatment dose groups for any of the depression scores used. Most patients completed the study; however, there was a high rate of reported adverse events, including voice alteration in 72.2% of patients, dyspnea in 32.3%, and pain in 31.7%. Interpretation of the IDS improvement over time is limited by the lack of a no-treatment control group. Approximately 20% of the patients included had a history of bipolar disorder; as such, the results might not be representative of most patients with treatment-resistant unipolar depression.

Conway et al (2025) reported results from the RECOVER trial, a multicenter, double-blind, sham-controlled RCT of VNS in 493 adults with treatment-resistant depression, defined as ≥ 4 failed adequate antidepressant treatments in a current DSM-5 major depressive episode.⁸² Participants were randomized to active VNS plus treatment-as-usual or to implanted but inactive sham VNS plus treatment-as-usual and followed for 12 months. The primary endpoint, the percentage of time in MADRS response from months 3 to 12, was not statistically significant (18.9% vs. 16.3%; odds ratio [OR], 1.17; 95% CI, 0.82 to 1.65; $p = .386$). Secondary outcomes showed benefits for active VNS: Clinical Global Impression-Improvement (CGI-I) response (26.7% vs. 18.2%; OR, 1.62; 95% CI, 1.17 to 2.24; $p = .004$), Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) response (25.2% vs. 19.8%; OR, 1.38; 95% CI, 1.00 to 1.89; $p = .049$). Remission rates were higher for VNS on CGI-I (8.0% vs 3.9%; OR, 2.07; 95% CI, 1.21 to 3.54; $p = .008$), though MADRS and QIDS remission did not differ. Dyspnea was more common in the active arm ($p = .035$), but no unexpected serious adverse events were observed. Rush et al (2025) reported on functional and quality-of-life outcomes in the same cohort at 12 months follow-up.⁴² Active VNS produced greater improvements in quality of life and functioning: Mini Quality of Life Enjoyment and Satisfaction Questionnaire (Mini-Q-LES-Q) (16.2% vs 13.3%; mean difference [MD], 2.9%; 95% CI, 0.0 to 5.8; $p = .050$) and Work Productivity and Activity Impairment (WPAI) item 6 (-2.1 vs -1.7; MD, -0.4; 95% CI, -0.8 to 0.0; $p = .05$). By contrast, Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total (MD, 2.3%; 95% CI, -0.1 to 4.8; $p = .061$), WHO Disability Assessment Schedule (WHODAS) (MD, -1.4; 95% CI, -4.1 to 1.3; $p = .304$), and EuroQol 5-Dimension Visual Analogue Scale (EQ-5D VAS) (MD, 2.1; 95% CI, -0.6 to 4.8; $p = .125$) did not significantly vary between groups.

Prospective Observational Studies

The observational study that compared patients participating in the RCT with patients in a separately recruited control group (D-04 versus D-02, respectively) evaluated VNS therapy out to 1 year and showed a statistically significant difference in the rate of change of depression score.^{43,35} However, issues such as unmeasured differences among patients, nonconcurrent controls, differences in sites of care between VNS therapy patients and controls, and differences in concomitant therapy changes raise concern about this observational study. Analyses performed on subsets of patients cared for in the same sites, and censoring observations after treatment changes, generally showed diminished differences in apparent treatment effectiveness of VNS and almost no statistically significant differences.⁴⁴ Patient selection for the randomized trial and the observational comparison trial may be of concern. VNS is intended for treatment-refractory depression, but the entry criteria of failure of 2 drugs and a 6-week trial of therapy might not be a strict enough definition of treatment resistance. Treatment-refractory depression should be defined by thorough psychiatric evaluation and comprehensive management. It is important to note that patients with clinically significant suicide risk were excluded from all VNS studies. Given these concerns about the quality of the

observational data, these results did not provide strong evidence for the effectiveness of VNS therapy.

Aaronson et al (2017) reported on results from the FDA required post-marketing surveillance study, which was a 5-year, prospective, open-label, nonrandomized observational study of the Treatment-Resistant Depression Registry.⁴⁵ The study compared treatment as usual, with or without adjunctive VNS. It was conducted at 61 sites in the United States and included 795 patients (VNS n=494, no VNS n=301) who were experiencing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had a history of 3 or more depressive episodes (including the current episode), and who had failed at least 4 prior depression treatments (including electroconvulsive therapy). Study treatment was patient-selected and/or assigned on an individualized basis at the discretion of the study site. The exception was for a subset of 159 (32%) VNS patients who were rolled over from the D-21 study (described above).³⁹ The primary efficacy outcome was the cumulative first-time 5-year response rate, defined as at least a 50% reduction in the MADRS score at any post-baseline visit. Due to its nonrandomized design, several significant between-groups differences were noted at baseline, including that the VNS group had a higher rate of past treatment with electroconvulsive therapy (57% vs. 40%; $p<.001$), a higher number of prior failed depression treatments (8.2 vs. 7.3; $p=.010$) more psychiatric hospitalizations within the 5 years before enrollment (3.0 vs. 1.9; $p<.001$) and lifetime suicide attempts (1.8 vs. 1.2; $p=.02$), and a higher mean MADRS score (33.1 vs. 29.3; $p<.001$). The propensity score method was used to adjust for these baseline imbalances. Clinical outcomes were significantly improved in the VNS groups, including higher cumulative first-time response (67.6% vs. 40.9%; $p<.001$) and cumulative first-time remission (MADRS total score ≤ 9 at any postbaseline visit, 43.3% vs. 25.7%; $p<.001$). The VNS arm also demonstrated a significantly greater reduction in suicidality on 2 of 3 different measures: Quick Inventory of Depressive Symptomatology Self Report (QIDSSR) item 12 (OR=2.11; 95% CI, 1.28 to 3.48), investigator-completed suicidality assessment (OR=2.04; 95% CI, 1.08 to 3.86), but not MADRS item 10 (OR=1.67; 95% CI, 0.98 to 2.83). There was no significant difference between the VNS and no VNS groups in completed suicides (1.01 per 1,000 person-years [95% CI=0.11 to 3.64] and 2.20 per 1,000 person-years [95% CI=0.24 to 7.79], respectively). Important limitations of the study include lack of a sham condition and the potential for bias due to confounding from unrestricted and uncontrolled concomitant treatments and bias in outcome measurement, which was unblinded. Additionally, other important outcomes such as quality of life and relapse were not reported.

McAllister-Williams et al (2020)⁴⁶ reported on results of a subgroup of 156 participants with treatment-resistant bipolar depression from the above-described FDA-required post-marketing surveillance study (Aaronson et al [2017]).⁴⁵ Compared to the overall population in the primary study, cumulative first-time response rates were similar in this bipolar depression subgroup (63% vs. 39%; p not reported). Median time-to-initial response was not significantly different between groups (13.7 vs. 42.1 months; Hazard Ratio [HR]=1.7; 95% CI, 1 to 2.7). Median time-to-relapse from initial response in the first year was also not significantly different between groups (15.2 vs. 7.6 months; HR=0.7; 95% CI, 0.3 to 1.4). Based on MADRS item 10, the mean reduction in suicidality score across the study visits was reportedly significantly greater in the VNS group than in the no VNS group ($p<.001$ as per F-test). However, the validity of this finding is unclear as by 60 months, it excluded data from an unacceptably high ($n=100$, 64%) and imbalanced (59% in VNS group vs. 73% in no VNS group) number of patients with unavailable suicidality data. It was additionally subject to the same important limitations as described above for the primary study.

Case series

Several case series published before the randomized trials showed rates of improvement with VNS, as measured by a 50% improvement in depression score, of 31% at 10 weeks to greater than 40% at 1 to 2 years, but there were some losses to follow-up.^{12,47,48} Natural history, placebo effects, and patient and provider expectations make it difficult to infer efficacy from case series data.

Other case series do not substantially strengthen the evidence supporting VNS. A case series by Bajbouj et al (2010), which followed patients for 2 years, showed that 53.1% (26/49) met criteria for a treatment response and 38.9% (19/49) met criteria for remission.³⁸ A small 2008 study of 9 patients with rapid cycling bipolar disorder showed improvements in several depression rating scales over 40 weeks of observation.⁴⁹ In a 2014 case series that included 27 patients with treatment-resistant depression, 5 patients demonstrated complete remission after 1 year, and 6 patients were considered responders.⁵⁰

Adverse events of VNS therapy included voice alteration, headache, neck pain, and cough, which are known from prior experience with VNS therapy for seizures. Regarding specific concerns for depressed patients (e.g., those with mania, hypomania, suicide, or worsening depression), there does not appear to be a greater risk of these events during VNS therapy.³⁵

Section Summary: Treatment-Resistant Depression

There are 3 RCTs evaluating the efficacy of implanted VNS for treatment-resistant depression compared to sham and 1 RCT comparing therapeutic to low-dose implanted VNS. Two sham-controlled trials reported only short-term results and found no significant improvement in the primary outcome with VNS. One sham-controlled trial with follow-up through 12 months found no difference in MADRS time in response between active and sham groups; however, several clinician and self-reported measures of symptom improvement showed a benefit for VNS (CGI, QIDS, Mini-Q-LES-Q, and WPAI). The low-dose VNS controlled trial reported no statistically significant differences between the dose groups for change in depression symptom score from baseline. Other available studies, which include nonrandomized comparative studies and case series, are limited by relatively small sample sizes and the potential for selection and confounding biases; the case series are further limited by the lack of control groups. Given the limitations of this literature, combined with the lack of substantial new clinical trials, the scientific evidence is considered to be insufficient to permit conclusions on the effect of this technology on major depression. Another neuromodulation technique (transcranial magnetic stimulation) for the treatment of depression is addressed in the medical policy “Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders.”

TREATMENT OF CHRONIC HEART FAILURE

Review of Evidence

Systematic Reviews

Sant'Anna et al (2021) conducted a systematic review and meta-analysis on clinical trials comparing VNS with medical therapy for the management of chronic heart failure with reduced ejection fraction.⁵¹ Four RCTs and 3 prospective studies were identified (N=1263). Only data from the 4 RCTs were included in the meta-analysis. The certainty of the evidence based on GRADE characteristics was reported as high for all outcomes. Characteristics of the systematic review are described in Table 8. The meta-analysis found significant improvements

in New York Heart Association functional class, quality of life, 6-minute walk test, and N-terminal-pro brain natriuretic peptide levels in patients treated with VNS compared to sham (Table 9).

Table 8. Characteristics of Systematic Reviews of Implantable VNS for Chronic Heart Failure

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Sant'Anna et al (2021) ⁵¹	1994 to 2020	7	Adults with heart failure with reduced ejection fraction	1263 (95 to 707)	4 RCTs, 3 prospective studies	median follow-up was 6 months (range: 6 to 16 months)

RCT: randomized controlled trial; VNS: vagus nerve stimulation

Table 9. Results of Systematic Reviews of RCTs of Implantable VNS for Chronic Heart Failure

Study	Improvement in NYHA functional class	Quality of Life ^a	6-minute walk-test	NT-proBNP levels	Mortality
Sant'Anna et al (2021) ⁵¹					
Total N	969 (4 RCTs)	450 (3 RCTs)	728 (3 RCTs)	445 (3 RCTs)	1206 (4 RCTs)
Pooled effect (95% CI)	OR, 2.72; (2.07 to 3.57); p<.0001	MD, -14.18 (-18.09 to -10.28)	MD, 55.46 meters (39.11 to 71.81)	MD, -144.25 (-238.31 to -50.18)	OR, 1.24 (0.82 to 1.89)
I ² (p)	37% (p<.0001)	49% (p<.0001)	0% (p<.0001)	65% (p=.003)	0% (p=.43)

CI: confidence interval; MD: mean difference; NT-proBNP: N-terminal-pro brain natriuretic peptide; NYHA: New York Heart Association; OR: odds ratio; RCT: randomized controlled trial; VNS: vagus nerve stimulation

^aAssessed by the Minnesota Living with Heart Failure Questionnaire (MLWHFQ)

Case Series

VNS has been investigated for the treatment of chronic heart failure in case series. A 2011 phase 2 case series of VNS therapy for chronic heart failure reported improvements in NYHA class quality of life, 6-minute walk test, and left ventricular (LV) ejection fraction.⁴⁴ The Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure With Preserved Ejection Fraction (ANTHEM-HF) trial (2014) is another case series, but in it, patients were randomized to right- or left-sided vagus nerve implantation (but without a control group).⁵² Overall, from baseline to 6-month follow-up, a number of measures were improved: LV ejection fraction improved by 4.5% (95% CI, 2.4% to 6.6%); LV end systolic volume improved by -4.1 mL (95% CI, -9.0 to 0.8 mL); LV end-diastolic diameter improved by -1.7 mm (95% CI, -2.8 to -0.7 mm); heart rate variability improved by 17 ms (95% CI, 6.5 to 28 ms); and 6-minute walk distance improved by 56 meters (95% CI, 37 to 75 meters). A follow-up analysis to ANTHEM-HF by Nearing et al (2021) evaluated outcomes of VNS at 12, 24, and 36 months.⁵¹ They found that LV ejection fraction improved by 18.7% (p=.008), 19.3% (p=.04), and 34.4% (p=.009) at 12, 24, and 36 months, respectively, with high-intensity VNS. Individuals with low-intensity VNS only had significant improvement in LV ejection fraction at 24 months (12.3%; p=.04).

Kumar et al (2023) published a case series in patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), called the ANTHEM-HFpEF trial.⁵⁴ Fifty-two patients with HFpEF or HFmrEF, NYHA class II to III on guideline-directed

medical therapy were successfully implanted with VNS therapy. At 12 months, NYHA class improved in 55% of patients ($p < 0.0001$), 6 minute walk test distance improved (mean, $300 \text{ m} \pm 71$ at 12 mo vs $288 \text{ m} \pm 78 \text{ m}$ at baseline; $p < 0.05$), and quality of life scores were improved compared to baseline ($p < 0.0001$).

Section Summary: Treatment of Chronic Heart Failure

The evidence on VNS for treatment of chronic heart failure consists of a systematic review including 4 RCTs and 3 uncontrolled studies. A meta-analysis of 4 RCTs found significant improvements in NYHA functional class, quality of life, 6-minute walk test, and N-terminal-pro brain natriuretic peptide levels in patients treated with VNS compared to sham. The uncontrolled studies consistently reported improvements on a variety of measures, including LV function, NYHA class, 6-minute walk test and quality of life. However, lack of a no-VNS comparator group precludes drawing conclusions based on findings from the uncontrolled studies.

TREATMENT OF UPPER-LIMB IMPAIRMENT DUE TO STROKE

Review of Evidence

Systematic Reviews

Ramos-Castaneda et al (2022) published a systematic review evaluating VNS on upper limb motor recovery after stroke.⁵⁵ Three RCTs by Dawson et al and Kimberley et al, which are summarized in the section below, were pooled for the analysis evaluating the role of implanted VNS. Results demonstrated that implanted VNS improved upper limb motor function based on Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score when compared to control (mean difference=2.78; 95% CI, 1.38 to 4.18).

Khan et al (2025) performed a systematic review and meta-analysis evaluating the effectiveness of pairing implanted vagus nerve stimulation (I-VNS) with rehabilitation therapy in ischemic stroke patients.⁸⁰ Their analysis included 8 studies, 4 were randomized controlled trials (RCTs), 3 were secondary or subgroup post hoc analyses of the Vagus Nerve Stimulation-Rehabilitation Randomized Controlled Trial (VNS-REHAB), and 1 was an exploratory study. The cumulative sample size was 498, with 245 individuals (49.1%) in the intervention group (I-VNS) and 252 (50.6%) in the control group. The mean age was 59.0 ± 10.01 years in the intervention group and 61.0 ± 9.7 years in the control group. The intervention group included 155 male patients (63.2%), and the control group had 165 male patients (64.4%). Both groups showed improvement in most outcomes post intervention and at follow-up. However, the intervention group demonstrated more significant improvements in FMA-UE scores compared with the control group. The pooled analysis showed a statistically significant improvement in upper extremity function with a mean difference of 3.16 (95% CI: 1.75-4.56) in Fugl-Meyer Assessment for Upper Extremity (FMA-UE). The minimal clinically important difference for Wolf Motor Function Test (WMFT) Functional Ability Scale (FAS) scores reported in literature is 0.2 to 0.4. In this review, the authors found a mean difference of 0.26 (95% CI: 0.14-0.39) in WMFT scores at 90 days, showing a small and statistically nonsignificant improvement in the intervention group compared with the control group. Limitations included the lack of demographic details and lack of data on relevant scales, such as the Stroke Impact Scale and Barthel Index. Also, lack of data on specific vascular territories and posterior circulation strokes places limitations on the generalization of outcomes for all the ischemic strokes. Last, the funding of 3 clinical trials by the same company makes it necessary

to replicate findings and conduct independent studies to ensure the results are reliable.⁸⁰ The authors concluded that I-VNS-paired rehabilitation improves functional outcomes and has a favorable safety profile in individuals with poststroke upper extremity weakness.

Randomized Controlled Trials

Dawson et al (2016) conducted a randomized pilot trial of VNS in patients with upper-limb dysfunction after ischemic stroke.⁵⁶ Twenty-one subjects were randomized to VNS plus rehabilitation or rehabilitation alone. The mean change in the outcome as assessed by a functional assessment score was +8.7 in the VNS group and +3.0 in the control group ($p=.064$). Six patients in the VNS group achieved a clinically meaningful response and 4 in the control group ($p=.17$). A similar RCT, the vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB), with a larger patient population was conducted by the same study group in 2021 (Dawson et al).⁵⁷ Patients with upper-limb dysfunction after ischemic stroke ($N=106$) were randomly assigned 1:1 to either VNS plus rehabilitation or rehabilitation with sham stimulation. The FMA-UE score increased by 5 points in the VNS group and 2.4 points in the control group (between-group difference, 2.6; 95% CI, 1.0 to 4.2; $p=.0014$). Ninety days after in-clinic therapy, a clinically meaningful response was achieved in 23 (47%) of 53 patients in the VNS group versus 13 (24%) of 55 patients in the control group (between-group difference, 24%; 95% CI, 6 to 41; $p=.0098$). There was 1 adverse event of vocal cord paresis related to surgery in the control group.

Kimberley et al (2019) reported results of a pilot sham-controlled RCT in 17 patients (VNS, $n=8$ and sham VNS, $n=9$) with arm weakness after ischemic stroke.⁵⁸ The mean FMA-UE scores increased by 7.6 with VNS versus 5.3 points with sham at day 1 (difference=2.3 points; 95% CI, -1.8 to 6.4; $p=.20$) and 9.5 points with VNS versus 3.8 with sham at day 90 (difference=5.7 points; 95% CI, -1.4 to 11.5; $p=.055$). A Fugl-Meyer assessment–upper extremity change ≥ 6 points was defined as response; the response rate at day 90 was 88% with VNS versus 33% with sham ($p<.05$). There were 3 serious adverse events related to surgery: wound infection, shortness of breath and dysphagia, and hoarseness because of vocal cord palsy.

Kimberley et al (2025) presented a post hoc analysis of data from the above 2021 trial conducted by Dawson et al.⁶⁰ The post hoc analysis reported unblinded, partial crossover, and pooled 1-year outcomes. 108 participants across 19 sites with chronic ischemic stroke and moderate-to-severe upper extremity impairment were enrolled in VNS-REHAB. Participants received 18 sessions of in-clinic intensive task-specific rehabilitation and 3 months of self-initiated home-based exercise with either real (active) or sham (control) vagus nerve stimulation. Thereafter, control participants crossed over to receive in-clinic therapy paired with active stimulation. All participants performed home-based exercises paired with self-initiated active stimulation for 1 year. The Fugl-Meyer Assessment UE, Wolf Motor Function Test, and participation outcomes were assessed through 12 months. Seventy-four participants (69%; 51 male; age, mean $\pm$ SD, 59.6 $\pm$ 8.9) completed 1-year follow-up and provided pooled data through 1 year.⁶⁰ At 1 year, compared with baseline, there were improvements in impairment (Fugl-Meyer Assessment UE, 5.23 [95% CI, 4.08-6.39]; $P<0.001$) activity (Wolf Motor Function Test, 0.50 [95% CI, 0.41-0.59]; $P<0.001$) and patient-reported outcomes (Motor Activity Log-Quality of Movement: 0.64 [95% CI, 0.46-0.82], $P<0.001$; Motor Activity Log-Amount of Use: 0.64 [95% CI, 0.46-0.82], $P<0.001$; Stroke Impact Scale-Activities of Daily Living: 7.43 [95% CI, 5.09-9.77], $P<0.001$; Stroke Impact Scale-Hand: 17.89 [95% CI, 14.16-21.63], $P<0.001$; EQ-5D: 5.76 [95% CI, 2.08-9.45], $P<0.05$; and Stroke Specific-Quality of Life: 0.29 [95% CI, 0.19-

0.39], $P < 0.001$) compared with baseline. The authors concluded that individuals treated with paired vagus nerve stimulation maintained improvements in UE impairment, activity, participation, and quality-of-life measures at 1 year. Limitations of the study include primarily unblinded outcome data, number of participants was small, missing data/no data was available for 31% of participants, and the self-initiated home exercise was not explicitly monitored.

Case Series

Saylor et al (2026) assessed real-world outcomes of a paired vagus nerve stimulation program at AdventHealth Sports Medicine and Rehabilitation, part of the AdventHealth Central Florida system.⁷⁹ This was a case series of stroke individuals who received care out of 10 outpatient clinics in central Florida. The individuals were implanted with a US Food and Drug Administration-approved vagus nerve stimulator and subsequently underwent at least 6 weeks of paired VNS therapy along with outpatient occupational therapy focused on high-repetition task practice. The individuals also engaged in self-initiated use of VNS paired with daily tasks outside of the therapy clinic for periods of 30 minutes up to 8 times per day. In total, 35 participants (21 men, 14 women), at least 6 months post ischemic stroke with moderate to severe upper extremity deficits. The average age was 59.2 ($\pm$ SD, 13.9) years, and participants were 3.7 ($\pm$ SD, 3.5) years poststroke.⁷⁹ The mean baseline Fugl-Meyer assessment upper extremity (FMA-UE) test score averaged 30.4 ($\pm$ SD, 10.2) points. After the period of in-clinic therapy, the average FMA-UE test score improved by 10.8 ($\pm$ SD, 5.4) points, with 28 of 35 (80%) participants classified as responders based on the FMA-UE test score's minimal clinically important difference of ≥ 6 points. The average box and block test score change was 4.5 blocks/min ($\pm$ SD, 2.9), with 10 of 23 meeting the minimal detectable change of 5.5 blocks. The authors concluded that VNS paired with rehabilitation therapy in patients with chronic ischemic stroke resulted in meaningful functional improvements aligned with individual patient goals in a real-world practice setting. Limitations of the study included the lack of blinding to the occupational therapists performing outcome measure testing, measures were often assessed by different occupational therapists, there was lack of standardization in testing the box and block test and patient-specific functional scale, with only 16 patients completing the patient-specific functional scale and 23 completing the box and block test. In addition, the sample size was small and there was no control group. Last, the results are from a single health center so the results may have limited generalizability.

Section Summary: Treatment of Upper-Limb Impairment Due to Stroke

The evidence on VNS for treatment of upper-limb impairment due to stroke consists of 3 small RCTs and a systematic review that pooled their data. Two RCTs compared VNS plus rehabilitation to rehabilitation alone, 1 failed to show significant improvements for the VNS group on response and function outcomes, but the other, which had a larger patient population, found a significant difference in response and function outcomes. The other RCT compared VNS to sham and found that although VNS significantly improved response rate, there were 3 serious adverse events related to surgery. The systematic review found that implanted VNS improved upper limb motor function based on FMA-UE score when compared to control.

OTHER NEUROLOGIC CONDITIONS (ESSENTIAL TREMOR, HEADACHE, FIBROMYALGIA, TINNITUS, AND AUTISM)

Review of Evidence

VNS has been investigated with small pilot studies or studies evaluating the mechanism of disease for several conditions. These conditions include essential tremor,¹⁸ fibromyalgia,⁵⁹ and tinnitus. The utility of VNS added to behavioral management of autism and autism spectrum disorders has been posited, but there are no RCTs.⁶¹ None of these studies are sufficient to draw conclusions on the effect of VNS on these conditions.

Section Summary: Other Neurologic Conditions (Essential Tremor, Headache, Fibromyalgia, Tinnitus, and Autism)

Other conditions have only been investigated with case series, which are not sufficient to draw conclusions on the effect of VNS.

PREVENTION OF CLUSTER HEADACHES

Clinical Context and Test Purpose

The purpose of noninvasive or transcutaneous vagus nerve stimulation (nVNS or tVNS) is to non-invasively apply low-voltage electrical currents to stimulate the cervical branch of the vagus nerve. NVNS has been tested primarily in the setting of headache. NVNS has been proposed as an intervention to reduce the frequency of attacks for cluster headaches as an adjunct to standard care.

REVIEW OF EVIDENCE

Systematic Reviews

A 2025 Ontario Health technology assessment evaluated the effectiveness of nVNS across RCTs.⁶³ One RCT (PREVA) was identified, which evaluated nVNS for preventive cluster headache and showed reductions in weekly attack frequency, higher response rates, and improvements in quality of life, with certainty of evidence rated low.

Randomized Controlled Trials

One RCT has evaluated nVNS for prevention of cluster headache compared to standard care. Characteristics of the trial are shown in Table 10. Results are shown in Table 11.

Table 10. Characteristics of RCTs of nVNS for Prevention of Cluster Headache

						Interventions	
Author (year); Trial	Countries	Sites	Dates	Participants	Randomized treatment period	Active	Comparator
Gaul et al (2016, 2017) ^{64,65} ; PREVA	Germany, UK, Belgium, Italy	10	2012 to 2014	18 to 70 y, cCH diagnosis	4 weeks	n=48; nVNS + SOC	n=49; SOC

cCH: chronic cluster headache; eCH: episodic cluster headache; nVNS: noninvasive vagus nerve stimulation; PREVA: PREvention and Acute treatment of chronic cluster headache; RCT: randomized controlled trial; SOC: standard of care.

Gaul et al (2016) reported on the results of a randomized open-label study of tVNS for the prevention of chronic cluster headache.⁶⁴ Forty-eight patients with chronic cluster headache were randomized to tVNS or individualized standard of care. Transcutaneous VNS was to be used twice daily with the option of additional treatment during headaches. At 4 weeks, the tVNS group had a greater reduction in the number of headaches than the control

group, resulting in a mean therapeutic gain of 3.9 fewer headaches per week ($p=.02$). Regarding response rate, defined as a 50% or more reduction in headaches, the tVNS group had a 40% response rate, and the control group had an 8.3% response rate ($p<.001$). The study lacked a sham placebo control group, which might have resulted in placebo response in the tVNS group. Gaul et al (2017) reported post-hoc, additional analyses of the PREvention and Acute treatment of chronic cluster headache (PREVA) study with varying definitions of response, e.g., attack frequency reductions of $\geq 25\%$, $\geq 75\%$, or ≥ 100 from baseline. Response consistently favored nVNS regardless of definition.

Table 11. Results of RCTs of nVNS for Prevention of Cluster Headache

Author (year); Study	Response (%)	Other efficacy outcomes		Quality of life or functional outcomes	Adverse events
	$\geq 50\%$ reduction in mean number of attacks (%)	Attack reduction from baseline per week (mean)	Acute medication use	EQ-5D-3L	≥ 1 Adverse event
Gaul et al (2016, 2017) ^{64,65} ; PREVA				Change from baseline	
n	93	93	Unclear	81	97
nVNS	40%	-5.9	-15	0.15	52%
SOC	8%	-2.1	-2	-0.05	49%
Treatment effect (95% CI)	NR; $p<.01$	3.9 (0.5 to 7.2); $p=.02$	NR	Difference=0.19 (0.05 to 0.33); $p<.01$	

CI: confidence interval; EQ-5D-3L: European Quality of Life 5 Dimensions 3 Level Version; NR: not reported; nVNS: noninvasive transcutaneous vagus nerve stimulation; PREVA: PREvention and Acute treatment of chronic cluster headache; RCT: randomized controlled trial; SOC: standard of care.

Relevance and design and conduct limitations are shown in Tables 12 and 13. The PREVA prevention study was not blinded and had no sham nVNS. The double-blind, study treatment period was less than 1 month, which limits inference about continued response.

Table 12. Study Relevance Limitations of RCTs of nVNS for Prevention of Cluster Headache

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Gaul et al (2016, 2017) ^{64,65} PREVA	2. Study population unclear				1: 4 week tx period, cannot assess continued response

nVNS: noninvasive transcutaneous vagus nerve stimulation; PREVA: PREvention and Acute treatment of chronic cluster headache; RCT: randomized controlled trial; tx: treatment.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use. 4. Enrolled populations do not reflect relevant diversity, 5. Other

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. the intervention of interest.

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not established and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 13. Study Design and Conduct Limitations of RCTs of nVNS for Prevention of Cluster Headache

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Gaul et al (2016, 2017) 64,65 ; PREVA		1: No blinding		1: Differential rate of missing data for quality of life measures (higher missing in nVNS)		

nVNS: noninvasive vagus nerve stimulation; PREVA: PREvention and Acute treatment of chronic cluster headache; RCT: randomized controlled trial.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4.

Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling

of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations

per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

The PREVA RCT also provided results from a 4-week open-label period. Results are shown in Table 14.

Table 14. Extended, Open-Label Follow-up of nVNS Patients From PREVA RCT

Author (year); Study	Response (%)	Attack frequency
Gaul et al (2016, 2017) 64,65 PREVA	≥50% reduction in mean number of attacks (%)	Attack reduction from randomized phase per week (mean)
Gaul et al (2016); PREVA (NCT01701245)		
n	45	30
4 wk follow-up	29%	2

nVNS: noninvasive vagus nerve stimulation; PREVA: PREvention and Acute treatment of chronic cluster headache; RCT: randomized controlled trial.

Nonrandomized and Observational Studies

To assess longer-term outcomes, non-randomized or observational prospective studies that capture longer periods of follow-up than the RCTs (> 1 month) and/or larger populations (with minimum n of 20) were sought. No such studies were identified.

Subsection Summary: Transcutaneous Vagus Nerve Stimulation for Prevention of Cluster Headaches

Transcutaneous (or noninvasive) VNS has been investigated for preventing cluster headaches in 1 RCT and 1 systematic review. The PREVA study of prevention of cluster headache in patients with chronic cluster headache demonstrated a statistically significant increase in the proportion of patients with a 50% or greater reduction in the mean number of headache attacks and statistically significant reduction in the frequency of attacks for nVNS compared to SOC with a treatment period of 4 weeks. There was also an improvement in quality of life as

measured by the European Quality of Life 5 Dimensions 3 Level Version. However, the study was not blinded. There are few adverse events of nVNS and they are mild and transient. The systematic review evaluating the same RCT found that nVNS reduced the frequency of weekly attacks and improved response rates in preventive cluster headache, however the certainty of evidence rated as low.

TREATMENT OF CLUSTER HEADACHES

Review of Evidence

Systematic Reviews

A 2025 Ontario Health technology assessment evaluated the effectiveness of nVNS across RCTs.⁶³ One RCT (PREVA) was identified, which evaluated nVNS for preventive cluster headache and showed reductions in weekly attack frequency, higher response rates, and improvements in quality of life, with certainty of evidence rated low.

Randomized Controlled Trials

Two RCTs have evaluated nVNS for treatment of acute cluster headache compared to sham nVNS. Treatment periods ranged from 2 weeks to 1 month. Characteristics of the trials are shown in Table 15. Results are shown in Table 16.

Table 15. Characteristics of RCTs of nVNS for Treatment of Cluster Headache

Author (year); Trial	Countries	Sites	Dates	Participants	Randomized Treatment Period	Interventions	
						Active	Comparator
Silberstein et al (2016) ⁶⁷ ; ACT1	U.S.	20	2013 to 2014	18 to 75 years of age, eCH or cCH diagnosis (3.3% Asian, 8% Black, 87.3% white, 1.4% race/ethnicity not reported)	Up to 1 month	n=73; nVNS	n=77; Sham
Goadsby et al (2018) ⁶⁸ ; ACT2	UK, Denmark, Germany, Netherlands	9	2013 to 2014	18 or older years of age; eCH or cCH diagnosis (99% white, 1% Asian)	2 weeks	n=50; nVNS	n=52; Sham

ACT1: Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache; ACT2: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache; cCH: chronic cluster headache; eCH: episodic cluster headache; nVNS: noninvasive vagus nerve stimulation; RCT: randomized controlled trial.

Silberstein et al (2016) reported on the results of a randomized, double-blind, sham-controlled study (ACT1) for treatment of acute cluster headache attacks.⁶⁷ One hundred fifty patients with cluster headaches were randomized to tVNS or sham treatment. Patients were further identified as having episodic cluster headaches or chronic cluster headaches and randomized at approximately 1:1 to the tVNS and sham treatment groups. The primary end point was response rate defined as the ability to achieve pain-free status within 15 minutes of initiation of treatment without rescue medication use through 60 minutes. Rescue medication was allowed after 15 minutes of nVNS or sham administration. There were no differences between tVNS-treated and sham-treated patients in the overall cluster headache study population. Subgroup

analysis of the chronic cluster headache population showed no differences between tVNS-treated and sham-treated patients. For the episodic cluster headache subgroup, tVNS demonstrated a 34.2% response rate compared with 10.6% response rate for sham-treated ($p=.008$). An interaction p -value for the subgroup analysis was not reported.

Goadsby et al (2018) reported on the results of randomized, double-blind, sham-controlled study (ACT2) for the treatment of acute cluster headache attacks.⁶⁸ Ninety-two patients with cluster headaches were randomized to tVNS (described in this response as noninvasive VNS) or sham treatment. Patients were further identified as having episodic cluster headaches or chronic cluster headaches and randomized at approximately 1:1 to the tVNS and sham treatment groups. The primary efficacy end point was the ability to achieve pain-free status within 15 minutes of initiation of treatment without use of rescue treatment. There was no difference between tVNS-treated and sham-treated patients in the overall cluster headache study population. Subgroup analysis of the chronic cluster headache population showed no differences between tVNS-treated and sham-treated patients. For the episodic cluster headaches subgroup, tVNS demonstrated a 48% response rate compared with 6% response rate for sham-treated ($p<.01$). The interaction p -value for the subgroup analysis was statistically significant ($p=.04$).

de Coo et al (2019) combined the data from ACT1 and ACT2 meta-analytically for the 2 primary outcomes reported in the 2 studies.⁶⁹ The authors reported an interaction between treatment group and cluster headache subtype in the pooled analysis ($p<.05$ for both outcomes).

Table 16. Results of RCTs of nNVS for Treatment of Cluster Headache

Author (year); Study	Response (%)	Other Efficacy Outcomes			Quality of Life or Functional Outcomes	Adverse Events
	Response (%)	Pain-free at 15 min (%)	Sustained response (%)			Adverse events (%)
Silberstein et al (2016) ⁶⁷ ; ACT1	First attack; Pain intensity score of 0 or 1 on a 5-point scale at 15 min	≥50% of attacks	Through 60 minutes	Rescue medication use	Quality of life or functional outcome	≥1 Adverse event
Overall						
n	133	133	133	133	NR	150
nVNS	27%	12%	27%	38%		25%
Sham	15%	7%	12%	51%		40%
Treatment effect (95% CI)	NR; $p=.10$	NR; $p=.33$	NR; $p=.04$	NR; $p=.15$		
By subgroup						
Treatment by subgroup interaction p -value	NR	NR	NR	NR		

cCH subgroup						
n	48	48	48	48	NR	
nVNS	14%	5%	14%	32%		
Sham	23%	15%	15%	54%		
Treatment effect (95% CI)	NR; p=.48	NR; p=.36	NR; p=1.0	NR; p=.13		
eCH subgroup						
n	85	85	85	85	NR	
nVNS	34%	16%	34%	42%		
Sham	11%	2%	11%	49%		
Treatment effect (95% CI)	NR; p=.01	NR; p=.04	NR; p=.01	NR; p=.53		
Goadsby et al (2018) ⁶⁸ ; ACT2	Proportion of attacks; Pain intensity score of 0 or 1 on a 5-point scale at 30 min	Proportion of attacks				
Overall						
n	92	92	NR	NR	NR	102
nVNS	43%	14%				40%
Sham	28%	12%				27%
Treatment effect (95% CI)	NR; p=.05	NR; p=.71				
By subgroup						
Treatment by subgroup interaction p-value		p=.04				
cCH subgroup						
n	66	66				
nVNS	37%	5%				
Sham	29%	13%				
Treatment effect (95% CI)	NR; p=.05	NR; p=.71				
eCH subgroup						
n	27	27				
nVNS	58%	48%				
Sham	28%	6%				
Treatment effect	NR; p=.07	NR; p<.01				

ACT1: Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache; ACT2: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache; CI: confidence interval; cCH: chronic cluster headache; eCH: episodic cluster headache; NR: not reported; nVNS: noninvasive transcutaneous vagus nerve stimulation; RCT: randomized controlled trial.

Relevance and design and conduct limitations are shown in Tables 17 and 18. The ACT1 and ACT2 treatment studies both included sham nVNS. The sham was identical in appearance, weight, visual and audible feedback, and user application and produced a low-frequency signal but did not generally cause muscle contraction. The double-blind study treatment period was less than one month in all three RCTs which limits inference about continued response. The ACT1 and ACT2 studies did not include quality of life or functional outcomes.

Table 17. Study Relevance Limitations of RCTs of nVNS for Treatment of Cluster Headache

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Silberstein et al (2016) ⁶⁷ ; ACT1	4. Enrolled populations not reflective of relevant diversity			1: No quality of life or functional outcomes reported.	1: Less than 1 month tx period, cannot assess continued response
Goadsby et al (2018) ⁶⁸ ; ACT2	4. Enrolled populations not reflective of relevant diversity			1: No measures of sustained pain freedom, relapse or quality of life or functional outcomes reported	1: 2 week tx period, cannot assess continued response

ACT1: Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache;

ACT2: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache; nVNS: noninvasive transcutaneous vagus nerve stimulation; RCT: randomized controlled trial; tx: treatment.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. the intervention of interest. c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 18. Study Design and Conduct Limitations of RCTs of nVNS for Treatment of Cluster Headache

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Silberstein et al (2016) ⁶⁷ ; ACT1						3: Interaction p not reported for treatment by cluster headache subtype
Goadsby et al (2018) ⁶⁸ ; ACT2				1: Differential rate of return of diaries in tx groups (4% missing in nVNS vs. 12% missing in sham)		

ACT1: Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache; ACT2: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®,

a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache; nVNS: noninvasive vagus nerve stimulation; RCT: randomized controlled trial; tx: treatment.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

The RCTs also provided results from open-label periods during which patients received nVNS ranging from 2 weeks in ACT2 to 3 months in ACT1. Patients continued to respond to nVNS during the open-label period. Results are shown in Table 19.

Table 19. Extended, Open-Label Follow-up of nVNS Patients From RCTs

Author (year); Study	Response (%)	Attack Frequency
	Response (%)	Pain-free at 15 min (%)
Silberstein et al (2016) ⁶⁷ ; ACT1	First attack; Pain intensity score of 0 or 1 on a 5-point scale at 15 min	≥50% of attacks
Overall		
n	NR	NR
3 mo follow-up		
cCH subgroup		
n	48	NR
3 mo follow-up	35% (95% CI, 22 to 51)	
eCH subgroup		
n	85	NR
3 mo follow-up	29% (95% CI, 20 to 40)	
Goadsby et al (2018) ⁶⁸ ; ACT2	Proportion of attacks; Pain intensity score of 0 or 1 on a 5-point scale at 30 min	Proportion of attacks
Overall		
n	NR	83
2 wk follow-up		14% (95% CI NR)

cCH subgroup		
n	NR	58
2 wk follow-up		11% (95% CI NR)
eCH subgroup		
n	NR	25
2 wk follow-up		26% (95% CI NR)

ACT1: Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache; ACT2: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache; CI: confidence interval; cCH: chronic cluster headache; eCH: episodic cluster headache; NR: not reported; nVNS: noninvasive vagus nerve stimulation; RCT: randomized controlled trial.

Nonrandomized and Observational Studies

To assess longer term outcomes, non-randomized or observational prospective studies that capture longer periods of follow-up than the RCTs (> 1 month) and/or larger populations (with minimum n of 20) were sought. No such studies were identified.

Subsection Summary: Transcutaneous Vagus Nerve Stimulation for Treatment of Cluster Headaches

VNS has been investigated for the treatment of cluster headaches in 2 RCTs and 1 systematic review. The ACT1 and ACT2 RCTs compared nVNS to sham for treatment of acute cluster headache in patients including both chronic and episodic cluster headache. The RCTs reported slightly different outcome measures so that consistencies in magnitude of treatment effects cannot be assessed. In ACT1, there was no statistically significant difference in the overall population in the proportion of patients with pain score of 0 or 1 at 15 minutes into the first attack (27% vs 15%, $p=.10$) and no difference in the proportion of patients who were pain-free at 15 minutes in 50% or more of the attacks (12% vs 7%, $p=.33$). However, in the episodic cluster headache subgroup ($n=85$) both outcomes were statistically significant favoring nVNS although the interaction p-value was not reported. In ACT2 the proportion of attacks with a pain intensity score of 0 or 1 at 30 minutes was statistically significant overall (43% vs 28%, $p=.05$). The proportion of attacks that were pain-free at 15 minutes was similar in the two treatment groups overall (14% vs 12%) but a significant interaction was reported ($p=.04$). There was a statistically significantly higher proportion of attacks in the episodic subgroup that were pain-free at 15 minutes in the nVNS group compared to sham (48% vs 6%, $p<.01$). Quality of life and functional outcomes have not been reported. Treatment periods ranged from only 2 weeks to 1 month with extended open-label follow-up of up to 3 months. Studies designed to test the effect of nVNS in the episodic subgroup with longer treatment and follow-up and including quality of life and functional outcomes are needed. The systematic review evaluating the same RCTs found that nVNS did not improve pain freedom, pain relief, or attack duration compared to controls, with certainty of evidence rated low to very low.

There are few adverse events of nVNS and they are mild and transient.

TREATMENT OF ACUTE MIGRAINE HEADACHES

Review of Evidence

Systematic Reviews

A 2025 Ontario Health technology assessment evaluated the effectiveness of nVNS for the acute treatment of migraine in 1 RCT (PRESTO).⁶³ The study found greater short-term pain relief at 2 hours with nVNS compared with sham, but no significant difference for sustained pain freedom. Overall, the certainty of evidence was rated moderate to low.

Randomized Controlled Trials

One RCT has evaluated nVNS for prevention of migraine headache compared to sham nVNS. Characteristics of the trials are shown in Table 20. Results are shown in Table 21. Relevance and design and conduct limitations are in Tables 22 and 23.

Table 20. Characteristics of RCTs of nVNS for Migraine Treatment

Author (year); Trial	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Tassorelli (2018) ⁷⁰ , Grazzi (2018) ⁷¹ , Martelletti (2018) ⁷² ; PRESTO (NCT02686034)	Italy	10	2016 to 2017	18 to 75 years of age, migraine diagnosis with or without aura; 3 to 8 attacks/month; <15 headache days/month over last 6 months (100% white)	n=122; nVNS	n=126; Sham nVNS

nVNS: noninvasive vagus nerve stimulation; PRESTO: A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS), for the Acute Treatment of Migraine; RCT: randomized controlled trial.

A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS) for the Acute Treatment of Migraine (PRESTO) trial was a multicenter, double-blind, randomized, sham-controlled trial of acute treatment of migraine with nVNS in 248 patients with episodic migraine with/without aura.⁷⁰ The primary efficacy outcome was the proportion of participants who were pain-free without using rescue medication at 120 minutes. There was not a statistically significant difference in the primary outcome (30% vs 20%; $p=.07$) although it favored the nVNS group. The nVNS group had a higher proportion of patients with decrease in pain from moderate or severe to mild or no pain at 120 minutes (41% vs 28%; $p=.03$) and a higher proportion of patients who were pain-free at 120 for 50% or more of their attacks (32% vs 18%; $p=.02$). PRESTO results did not include quality of life or functional outcomes and the double-blind treatment and follow-up period was 4 weeks. In the additional 4 weeks of acute nVNS in the open-label period, rates of pain-free response after the first treated attack (28%,) and pain relief (43.4%) were similar to the rates in the double-blind period.

Table 21. Results of RCTs of nVNS for Migraine Treatment

Author (year); Study	Pain-relief (%)	Pain-free (%)	Response Over Multiple Attacks (%)	Sustained Response / Relapse or Recurrence Over 48 Hours	Rescue Medication Use	Quality of Life or Functional Outcomes	Adverse Events (%)

Tassorelli (2018) ⁷⁰ Grazzi (2018) ⁷¹ Martelletti(2018) ⁷² PRESTO (NCT02686034)	Decrease in pain intensity from moderate (2) or severe (3) to mild (1) or no (0) pain on a 4-point scale at 120 minutes, first attack	Pain-free without using rescue medication at 120 minutes, first attack	Pain-free at 120 minutes for ≥50% of their attacks	Sustained pain-free response at 48 hours, first attack	Did not required rescue medication (%)		≥1 Adverse event
n	243	243	243	62	243	NR	248
nVNS	41%	22%	32%	58%	59%		18%
Sham	28%	13%	18%	69%	42%		18%
Treatment effect (95% CI)	Difference=13% (NR); p=.03	Difference=11% (NR); p=.07	Difference=14% (NR); p=.02	NR; p=.38	NR; p=.01		

CI: confidence interval; nVNS: noninvasive vagus nerve stimulation; NR: not reported;

PRESTO: A Prospective, Multi-centre, Randomized, Double-blind,

Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS), for the Acute Treatment of Migraine;

RCT: randomized controlled trial.

Table 22. Study Relevance Limitations of RCTs of nVNS for Treatment of Migraine Headache

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Tassorelli (2018); PRESTO	4. Enrolled populations not reflective of relevant diversity			1: No quality of life or functional outcomes reported	1: 4 week tx period, cannot assess continued response

nVNS: noninvasive vagus nerve stimulation; PRESTO: A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS), for the Acute Treatment of Migraine; RCT: randomized controlled trial; tx: treatment

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest; 5. Not delivered effectively

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 23. Study Design and Conduct Limitations of RCTs of nVNS for Treatment of Migraine Headache

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Tassorelli (2018); PRESTO						

nVNS: noninvasive vagus nerve stimulation; RCT: randomized controlled trial; PRESTO: A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS), for the Acute Treatment of Migraine. The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Nonrandomized and Observational Studies

To assess longer term outcomes, non-randomized or observational prospective studies that capture longer periods of follow-up than the RCTs (> 2 months) and/or larger populations (with minimum n of 20) were sought.

Trimboli et al (2018) reported on the preventive and acute treatment of nVNS in 41 consecutive patients with refractory primary chronic headaches (n=23 with chronic migraine) in an open-label, prospective, noncomparative clinical audit. Response was defined as at least 30% reduction in headache days/episodes after three months of treatment. Two of 23 (9%) chronic migraine patients met the definition for responder.⁷³

Subsection Summary: Transcutaneous Vagus Nerve Stimulation for Migraine Headaches

One RCT has evaluated nVNS for the acute treatment of migraine in 248 patients with episodic migraine with/without aura. There was not a statistically significant difference in the primary outcome of the proportion of participants who were pain-free without using rescue medication at 120 minutes (30% vs 20%; p=.07). However, the nVNS group had a higher proportion of patients with decrease in pain from moderate or severe to mild or no pain at 120 minutes (41% vs 28%; p=.03) and a higher proportion of patients who were pain-free at 120 minutes for 50% or more of their attacks (32% vs 18%; p=.02). There are few adverse events of nVNS and they are mild and transient. Quality of life and functional outcomes were not reported and the double-blind treatment period was 4 weeks with an additional 4 weeks of open-label treatment. Given the marginally significant primary outcome, lack of quality of life or functional outcomes and limited follow-up, further RCTs are needed. A systematic review evaluating the same RCT found that nVNS reduced short-term pain but provided no sustained benefit for pain freedom relative to control participants, with the certainty of evidence rated as moderate to low.

PREVENTION OF MIGRAINE HEADACHES

Review of Evidence

Three RCTs have evaluated nVNS for prevention of migraine headache compared to sham. Characteristics of the trials are shown in Table 24. Results are shown in Table 25. Relevance and design and conduct limitations are in Tables 26 and 27.

Systematic Reviews

A 2025 Ontario Health technology assessment evaluated the effectiveness of nVNS for the prevention of migraine in episodic and chronic populations across 4 RCTs.⁶³ Findings were inconsistent, with only small reductions in monthly migraine or headache days compared with sham. Some studies reported trends toward reduced acute medication use; however, the

results did not consistently achieve statistical significance. The certainty of evidence for preventive migraine was judged low to very low.

Randomized Controlled Trials

Table 24. Characteristics of RCTs of nVNS for Migraine Prevention

Author (year); Trial	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Silberstein (2016) ⁷⁴ ; EVENT (NCT01667250)	U.S.	6	2012 to 2014	18 to 65 years of age, chronic migraine diagnosis with or without aura; <15 headache days/month over last 3 months (86.4% white, 5.1% black, 8.5% race/ethnicity not reported)	n=30; nVNS	n=29; sham nVNS
Diener (2019) ⁷⁵ ; PREMIUM (NCT02378844)	Belgium, Denmark, Germany, Greece, Netherlands, Norway, Spain, U.K.	22	2015 to 2017	18 to 75 years of age, migraine diagnosis with or without aura, 5–12 migraine days per month over past 4 months with at least 2 migraines lasting more than 4 hours (94.9% white, 5.1% race/ethnicity not reported)	n=169 nVNS	n=172 sham nVNS
Najib et al (2022) ⁷⁶ ; PREMIUM II	U.S.	27	2018 to 2020	18 to 75 years of age; episodic or chronic migraine with or without aura; 8 to 20 headache days per month over past 3 months with at least 5 of the days being migraine days (migraines lasting more than 4 hours or treated with migraine-specific treatment); (>91% White Individuals enrolled)	n=114nVNS	N=117 sham

EVENT: Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Prevention of Chronic Migraine; nVNS: noninvasive vagus nerve stimulation; PREMIUM: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine; PREMIUM II: A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines; RCT: randomized controlled trial.

The EVENT trial was a feasibility study of prevention with a sample size of 59 patients . It was not powered to detect differences in efficacy outcomes.⁷⁴ For the outcome of response, defined as 50% or more reduction in the number of headache days, 10% of the patients in the nVNS group versus 0% in the sham group were responders; statistical testing was not performed.

The PREMIUM trial was a phase 3, multicenter, sham-controlled RCT conducted in several European countries including patients who experienced 5 to 12 migraine days per month.⁷⁵ The study included a 4-week run-in period during which no treatment was administered; 477 participants entered the run-in. The criteria to remain eligible after run-in were not described in the publication. After run-in, 341 participants were randomized (nVNS, n=169 or sham, n=172) to a 12-week double-blind treatment period followed by a 24-week open-label period of nVNS. Patients administered two 120-second stimulations bilaterally to the neck with gammaCore, 3 times daily. Results showed that nVNS was not statistically significantly superior to sham with respect to the outcomes of reduction of at least 50% in migraine days from baseline to the last 4 weeks, reduction in number of migraine days from baseline to the last 4 weeks or acute medication days in the intention-to-treat (ITT) population.

The PREMIUM II trial was a multicenter, sham-controlled RCT conducted in several U.S. sites and included Individuals who experienced 8 to 20 headache days per month with at least 5 of the days being migraine days.⁷⁶ The study included a 4-week run-in period during which no treatment was administered (N=336). After the run-in period, 231 patients were randomly assigned to receive nVNS (n = 114) or sham (n = 117) therapy during the double-blind period and were part of the ITT population (i.e., had ≥1 study treatment during the double-blind phase). The COVID-19 pandemic led to an early termination of this trial, therefore, the population was approximately 60% smaller than the statistical target for full power. The modified ITT (mITT) population, which included those who were at least 66% adherent to treatment during the double-blind phase, included 56 patients in the nVNS group and 57 in the sham group. Results showed that in the mITT population, nVNS was not statistically significantly superior to sham with respect to the primary outcome of reduction in the number of migraine days per month during weeks 9 through 12 (mean difference=-0.83 days; p=.2329), nor other outcomes such as mean change in the number of headache days or acute medication days. However, in the mITT population, the percentage of Individuals with at least a 50% reduction in the number of migraine days was significantly greater in the nVNS group (44.87%) than in the sham group (26.81%; p=.048). Furthermore, nVNS was significantly better than sham at decreasing headache impact, as measured by the Headache Impact Test-6 (HIT-6), and at decreasing migraine-related disability, as measured by the Migraine Disability Assessment Scale (MIDAS).

Table 25. Results of RCTs of nVNS for Migraine Prevention

Author (year); Study	Response (%)	Frequency of Headache	Other Medication Use	Quality of Life or Functional Outcomes	Adverse Events (%)
Silberstein (2016) ⁷⁴ ; EVENT (NCT01667250)	≥50% reduction in number of headache days	Change from baseline in number of headache days / 28 days	Acute medication		≥1 Adverse event
n	59	59	59	NR	59
nVNS	10%	-1.4	NR		57%
Sham	0%	-0.2	NR		55%
Treatment effect (95% CI)	Odds Ratio=1.40 (0.85, 2.32); p=.19	Difference=-0.47 (CI NR); p=.15	p=.11		NR
Najib et al (2022) ⁷⁶ ; PREMIUM II	≥50% reduction in number of headache days	Mean change in number of migraine days	Acute medication days	Mean change in HIT-6 score	
N	113	113	113	88	
nVNS	44.87%	-4.56	-2.53	-4.9	
Sham	26.81%	-2.29	-1.36	-2.3	

Treatment effect (95% CI)	OR=2.22 (CI NR); p=.0481	Difference=-0.83 (CI NR); p=.2329	Difference=-1.17 (CI NR); p=.1132	Difference=-2.6 (CI NR); p=.0250	
		Mean change in number of headache days		MIDAS shift from moderate/severe to none/mild	
N		113		88	
nVNS		-4.56		25%	
Sham		-3.00		9.1%	
Treatment effect (95% CI)		Difference=-1.56 (CI NR); p=.0530		15.9% (CI NR); p=.0472	
Diener (2019) ⁷⁵ ; PREMIUM (NCT02378844)	Reduction of at least 50% from baseline to the last 4 weeks	Reduction in number of migraine days from baseline to the last 4 weeks (Mean days)	Acute medication days		≥1 Adverse event
n	332	332	332	NR	341
nVNS	32%	-2.3	-1.9		44%
Sham	25%	-1.8	-1.4		53%
Treatment effect (95% CI)	OR= 1.40 (0.85, 2.32); p=.19	Difference=-0.47 (CI NR); p=.15	p=.11		

CI: confidence interval; EVENT: Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Prevention of Chronic Migraine; HIT-6: Headache Impact Test-6; MIDAS: Migraine Disability Assessment; OR, odds ratio
nVNS: noninvasive vagus nerve stimulation; NR: not reported; PREMIUM: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine; RCT: randomized controlled trial. PREMIUM II: A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines; RCT: randomized controlled trial.

Table 26. Study Relevance Limitations of RCTs of nVNS for Prevention of Migraine Headache

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Silberstein (2016) ⁷⁴ ; EVENT (NCT01667250)	4. Enrolled populations not reflective of relevant diversity	5: ~20% of participants discontinued tx during first 2 months	2: Sham did not deliver electrical stimulations, may have compromised blinding 4: ~20% of participants discontinued tx during first 2 months	1: No quality of life or functional outcomes reported.	1: 2 month tx period, cannot assess continued response
Diener (2019) ⁷⁵ ; PREMIUM (NCT02378844)	4. Enrolled populations not reflective			1: No quality of life or functional outcomes reported.	1: 12-week double-blind tx period, cannot

	of relevant diversity				assess continued response
Najib et al (2022) ⁷⁶ ; PREMIUM II	4. Enrolled populations not reflective of relevant diversity		1. Not clearly defined; unclear if sham device delivered electrical stimulations		1: 12-week double-blind tx period, cannot assess continued response

EVENT: Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Prevention of Chronic Migraine; nVNS: noninvasive vagus nerve stimulation; PREMIUM: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine; RCT: randomized controlled trial; tx: treatment PREMIUM II: A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines;

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations not reflective of relevant diversity; 5. Other .

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest; 5. Not delivered effectively

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 27. Study Design and Conduct Limitations of RCTs of nVNS for Prevention of Migraine Headache

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Silberstein (2016); EVENT					1,2,3: No formal sample size calculations or efficacy hypotheses; primarily a feasibility RCT. Probably low power to detect difference in efficacy outcomes	
Diener (2019); PREMIUM (NCT02378844)						
Najib et al (2022) ⁷⁶ ; PREMIUM II						

EVENT: Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Prevention of Chronic Migraine; nVNS: noninvasive vagus nerve stimulation; PREMIUM: A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine; RCT: randomized controlled trial.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Nonrandomized and Observational Studies

To assess longer-term outcomes, non-randomized or observational prospective studies that capture longer periods of follow-up than the RCTs (> 2 months) and/or larger populations (with minimum n of 20) were sought.

Grazzi et al (2016) reported on the use of preventive nVNS in an open-label, prospective, noncomparative study of 56 women with menstrual migraine. The treatment period was 12 weeks. At the end of treatment, the mean number of headache days per month was reduced from baseline (7.2 to 4.7; $p < .01$). Twenty patients (39%; 95% CI, 26% to 54%) had a $\geq 50\%$ reduction in headache days.⁷⁷

Kinfe et al (2015) enrolled 20 patients with treatment-refractory migraine in this 3-month, open-label, prospective, noncomparative observational study of preventive nVNS. The number of headache days per month decreased from 14.7 to 8.9 ($p < .01$) between baseline and end of treatment (3 months). The migraine disability assessment score improved from 26 to 15 ($p < .01$).⁷⁸

Subsection Summary: Transcutaneous Vagus Nerve Stimulation for Prevention of Migraine Headaches

Three RCTs and 1 systematic review have evaluated nVNS for prevention of migraine. The EVENT trial was a feasibility study of prevention of migraine that was not powered to detect differences in efficacy outcomes. It does not demonstrate the efficacy of nVNS for prevention of migraine. The PREMIUM trial was a phase 3, multicenter, sham-controlled RCT including 341 randomized participants with a 12-week double-blind treatment period. The results of PREMIUM demonstrated that nVNS was not statistically significantly superior to sham. With respect to the outcomes of reduction of at least 50% in migraine days from baseline to the last 4 weeks, reduction in number of migraine days from baseline to the last 4 weeks or acute medication days. The PREMIUM II trial was a multicenter, sham-controlled RCT including 231 randomized participants with a 12-week double-blind treatment period. Results demonstrated that treatment with nVNS was not statistically significantly superior to sham with respect to the primary outcome of reduction in the number of migraine days per month during weeks 9 through 12, nor other outcomes such as mean change in the number of headache days or acute medication days. However, the percentage of participants with at least a 50% reduction in the number of migraine days was significantly greater in the nVNS group than in the sham group. However, interpretation of these findings is limited as it was based on a mITT population of 49% of randomized patients ($n = 113$ of original 231 participants) due to COVID-19 pandemic-related early termination. The systematic review found that nVNS resulted in only small reductions in monthly migraine or headache days compared with sham, and the results did not consistently achieve statistical significance. The certainty of evidence for preventive migraine was judged low to very low.

RHEUMATOID ARTHRITIS

Clinical Context and Therapy Purpose

Review of Evidence

Randomized Controlled Trials

Two RCTs have evaluated VNS for the treatment of RA compared to sham VNS. Characteristics of the trials are shown in Table 28. Results are shown in Table 29. Genovese et al (2020) conducted a multicenter, randomized pilot trial of an implantable VNS device in patients with multidrug-refractory rheumatoid arthritis.⁸³ Fourteen patients with moderately to severely active RA who had failed at least 2 biologic or targeted synthetic DMARDs with different mechanisms of action were enrolled across two stages. In Stage 1 (n=3), all patients received active stimulation once daily for safety evaluation. In Stage 2 (n=11), participants were randomized 1:1:1 to active stimulation once daily, active stimulation 4 times a day, or sham. At 12 weeks, 5 (50%) treated patients achieved clinically meaningful improvements in DAS28-CRP (≥ -1.2) and CDAI ($\geq$ MCID), whereas none of the sham-treated patients met these thresholds. Two patients achieved DAS28-CRP remission (<2.6), and European Alliance of Associations for Rheumatology (EULAR) good or moderate responses were seen in 50% of treated patients compared with 0% in sham. Safety was the primary endpoint, and no device-related or stimulation-related serious adverse events were reported. Two surgery-related complications occurred: 1 case each of vocal cord paralysis and Horner's syndrome, both resolving over several months without permanent sequelae. Additional mild or moderate adverse events included dermatitis, pruritus, postprocedural inflammation, and procedural pain, each in isolated patients.

The RESET-RA trial is an ongoing randomized, double-blind, sham-controlled study in patients with moderate-to-severe RA and inadequate response to 1 or more b/tsDMARDs.[Peterson D, Van Poppel M, Boling W, et al. Clinica.... 2024; 10(1): 8. PMID 38475923] The interim publication by Peterson et al (2024) established safety and feasibility, with implantation completed successfully with no intra-operative complication, infections, and no surgical revisions required. All reported adverse events were mild to moderate. Additional outcome data were published by the manufacturer in the SetPoint System Instructions for Use (IFU), and have not been published in the peer-reviewed literature. The RESET-RA trial population, as reported in the IFU, enrolled 242 patients.⁸⁵ The primary endpoint, ACR20 response at Week 12, was met by 35.2% of the treatment group vs 24.2% of controls, an absolute difference of 11.8 percentage points (95% CI, 0.6 to 23.1; $p=.0209$). Secondary endpoints included disease activity and function. A clinically meaningful DAS28 improvement (MCID -1.2) was achieved in 45.1% of treated patients vs 32.5% in controls (difference 13.2%; 95% CI, 1.1 to 25.3; $p=.0528$). For physical function, a HAQ-DI improvement (MCID ≤ -0.22) occurred in 45.9% vs 36.7% (difference 9.0%; 95% CI, -3.3 to 21.4; $p=.0797$). Open-label follow-up through Week 48 showed sustained and in some cases increasing response rates across ACR20, DAS28, and HAQ-DI. Through 3-month follow-up, non-serious adverse events occurred in 13.9% of treated and 18.3% of controls, most related to implantation. Serious adverse events related to procedure or device occurred in 1.6% of patients, including isolated cases of incision site swelling, vocal cord paresis, dysphonia, and one pharyngeal perforation; all resolved without death or treatment discontinuation. During long-term follow-up, stimulation-related AEs were uncommon (5%), all mild or moderate, and included poor sleep, implant site discomfort, trigeminal neuralgia exacerbation, dysphonia, implant site pain, muscle spasms, presyncope, and temporomandibular joint syndrome. Fourteen implants (5.8%) were explanted over a mean of 469 days.

Table 28. Characteristics of RCTs of VNS for Rheumatoid Arthritis

					Interventions		
Author (year); Trial	Countries	Sites	Dates	Participants	Randomized treatment period	Active	Comparator
Peterson et al (2024) ^{84,85} ; RESET-RA	U.S.	41	2021 to 2022	Adults 22 to 75 years of age with moderate to severe RA; inadequate/loss of response or intolerance to ≥ 1 b/tsDMARD; on stable csDMARD ≥ 12 weeks	12 weeks	SetPoint implant on left cervical vagus; 1-min once daily; 10 Hz; 0.25 ms; n=122	n=120
Genovese et al (2020) ⁸³	U.S.	5	2018	Adults 22 to 75 years of age with multidrug-refractory RA; prior insufficient response to ≥ 2 DMARDs with ≥ 2 mechanisms; active disease by ACR/EULAR criteria	12 weeks	Active VNS: 1 min once daily (n=3) or 1 min four times daily (n=4)	n=4

ACR: American College of Rheumatology; bDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DMARD: disease-modifying antirheumatic drug; EULAR: European Alliance of Associations for Rheumatology; RA: rheumatoid arthritis; tsDMARD: targeted synthetic disease-modifying antirheumatic drug.

Table 29. Results of RCTs of VNS for Rheumatoid Arthritis

Author (year); Study	ACR20	DAS28	HAQ-DI	Adverse events (%)
Peterson et al (2024) ^{84,85} ; RESET-RA	Week 12: % achieving ACR20	Week 12: % achieving MCID ≤ -1.2	Week 12: % achieving MCID ≤ -22	Week 12: Any AE
VNS n=122	35.2%	45.1%	45.9%	13.9%
Sham n=120	24.2%	32.5%	36.7%	18.3%
Treatment effect (95% CI)	+11.8% (95% CI, 0.6 to 23.1); p=.0209	+13.2% (95% CI, 1.1 to 25.3); p=.0528	+9.0% (95% CI -3.3 to 21.4); p=.0797	NR
Genovese et al (2020) ⁸³	Week 12: % achieving ACR20	Week 12: % achieving MCID ≤ -1.2		Week 12: Any AE
VNS n=7	20%	50%		57%
Sham n=4	0%	0%		50%
Treatment effect (95% CI)	NR	NR		NR

ACR20: 20% improvement per American College of Rheumatology responder criteria; AE: adverse event; CI: confidence interval; DAS28: Disease Activity Score in 28 joints; HAQ-DI: Health Assessment Questionnaire–Disability Index; MCID: minimal clinically important difference; NR: not reported; VNS: vagus nerve stimulation.

Table 30. Study Relevance Limitations of RCTs of VNS for Rheumatoid Arthritis

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Peterson et al (2024) ^{84,85} ; RESET-RA	4. Enrolled populations not reflective of relevant diversity		2: Sham did not deliver electrical stimulations, may have compromised blinding		
Genovese et al (2020) ⁸³	4. Enrolled populations not reflective of relevant diversity		2: Sham did not deliver electrical stimulations, may have compromised blinding		1: 12-week tx period, cannot assess continued response

tx: treatment

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest; 5. Not delivered effectively

c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 31. Study Design and Conduct Limitations of RCTs of VNS for Rheumatoid Arthritis

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Peterson et al (2024) ^{84,85} ; RESET-RA			4. Outcome data not presented in peer-reviewed literature	2,3,4. Loss to follow-up unclear in longer-term data; crossover after Week 12 limits long-term comparative data	1. Power calculations not reported	
Genovese et al (2020) ⁸³	3. Allocation concealment unclear				1. Power calculations not reported	3, 4. Descriptive reporting of outcomes in this pilot trial; comparative CIs are not provided for outcomes

CI: confidence interval.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Subsection Summary: Transcutaneous Vagus Nerve Stimulation for Rheumatoid Arthritis

Two randomized, sham-controlled trials have evaluated the use of implantable VNS for the treatment of RA. One RCT was a pilot study in multidrug-refractory RA, which demonstrated procedural feasibility and safety. The ACR20 and DAS28 outcomes were numerically superior for the VNS group; however, these differences were not statistically compared, as the study wasn't powered for effectiveness. The pivotal RESET-RA trial was a multicenter, double-blind, sham-controlled RCT with a 12-week blinded period; published peer-reviewed results show a high rate of implant success but do not report additional outcomes. The manufacturer's IFU reports statistical superiority of implantable VNS over sham for the prespecified primary responder endpoint, ACR20, but no significant differences on secondary clinical and functional outcomes (DAS28, CDAI, and HAQ-DI). Safety across studies was acceptable, with mostly mild stimulation-related events and infrequent surgery-related complications. Evidence for implantable VNS remains limited to a small feasibility RCT that was not powered for efficacy, as well as a single pivotal, sham-controlled trial with outcome assessment only available in manufacturer documents, which has not yet been peer-reviewed. Overall, the certainty of evidence for RA remains limited, and an additional large, peer-reviewed RCT with longer blinded follow-up is warranted.

OTHER NEUROLOGIC, PSYCHIATRIC, OR METABOLIC DISORDERS,

Clinical Context and Therapy Purpose

The purpose of nVNS or tVNS is to non-invasively apply low-voltage electrical currents to stimulate the cervical branch of the vagus nerve. nVNS has been tested primarily in the setting of headache. Proposed uses have been tested in other neurologic, psychiatric, or metabolic disorders as well.

Review of Evidence

Epilepsy

Wu et al (2020) reported results of a systematic review and meta-analysis of 3 RCT's (N=280, range n=60 to 144)^{86,87,88} of tVNS for the treatment of drug-resistant epilepsy⁸⁹. All treatment groups underwent a cymba conchae stimulus at a frequency of 20 to 30-Hz. The control groups received various kinds of sham stimulation at a frequency of 1 HZ, the same frequency stimulation as treatment but at the non-auricular vagus nerve area or no stimulation. Meta-analysis of all 3 included RCTs found that seizure frequency was significantly reduced with tVNS (Mean Difference [MD]=-3.29; 95% CI, -6.31 to -0.27). However, meta-analysis of the 2 RCTs that reported responder rates (undefined) did not find a significant difference between the tVNS and control groups (N=238; OR=1.47; 95% CI, 0.54 to 4.02]. All 3 RCTs assessed quality of life using the Quality of Life in Epilepsy Inventory (QOLIE)-31 scale, but found no significant differences between treatment and control groups. Important limitations of the RCTs include imprecision, risk of confounding due to potentially imbalanced use of important non-protocol interventions (ie, concomitant antiepileptic drugs), and unacceptable flaws in outcome assessment (ie, unspecified definition of response, between-group differences in measurement timing, lack of electroencephalography data). Another RCT by Yang et al (2023), published

after the meta-analysis, found similar results.⁹⁰ In total, 150 patients with drug-resistant epilepsy were randomized to tVNS (n=100) or sham VNS (n=50). The patient's current antiepileptic drugs were unchanged throughout the study. At 20 weeks of treatment, investigators found that response to treatment (experiencing $\geq 50\%$ reduction in mean seizure frequency) was significantly higher with tVNS (44.74%) compared to sham (16.67%; $p < .05$). However, there were no significant differences in quality-of-life scores between groups. These results are limited by the small sample size and high dropout rate (25.3%).

Shi et al (2025) reported the results of a meta-analysis of neuromodulatory therapies for drug-resistant epilepsy, which included 8 VNS studies (5 invasive and 3 transcutaneous auricular VNS) among 28 total studies.⁹¹ The analysis examined seizure-frequency reduction via both a Bayesian network meta-analysis and a single-arm meta-analysis. In the network meta-analysis versus anti-seizure medication controls, neither invasive VNS (OR, 1.17; 95% CI, 0.59 to 2.28) nor transcutaneous auricular VNS (OR, 1.23; 95% CI, 0.69 to 2.22) demonstrated superiority. In a single-arm meta-analysis of SMA pooling pre- and post-data, both modalities were associated with significant improvement: invasive VNS (OR, 1.83; 95% CI, 1.58 to 2.13) and transauricular VNS (OR, 1.73; 95% CI, 1.06 to 2.83). In long-term analyses of ≥ 3 years, a significant reduction in seizure frequency was observed (OR, 2.84; 95% CI, 1.55 to 5.18), although it was ranked behind deep brain stimulation and RNS at extended follow-up. Key limitations included substantial heterogeneity, reliance on open-label extensions in the single-arm meta-analysis, and low to moderate certainty for comparative effects in the network meta-analysis.

Psychiatric Disorders

Hein et al (2013) reported on results of 2 pilot RCTs of a t-VNS device for the treatment of depression, one of which included 22 subjects and another assessed 15 subjects. In the first study, 11 subjects were randomized to active or sham tVNS.⁹⁴ At 2-week follow-up, Beck Depression Inventory (BDI) self-rating scores in the active stimulation group decreased from 27.0 to 14.0 points ($p < .001$), while the sham-stimulated patients did not show significant reductions in BDI scores (31.0 to 25.8 points). In the second study, 7 patients were randomized to active tVNS, and 8 patients were randomized to sham tVNS. In this study, BDI self-rating scores in the active stimulation group decreased from 29.4 to 17.4 points ($p < .05$) after 2 weeks, while the sham-stimulated patients did not show a significant change in BDI scores (28.6 to 25.4 points). The authors did not report direct comparisons in BDI change scores between the sham- and active-stimulation groups. One RCT of transcutaneous VNS for treatment of major depressive disorder has been registered in clinicaltrials.gov with a completion date of July 2016 (NCT02562703) but appears to be unpublished.

Hasan et al (2015) reported on a randomized trial of t-VNS for the treatment of schizophrenia.⁹² Twenty patients were assigned to active t-VNS or sham treatment for 12 weeks. There was no statistically significant difference in the improvement of schizophrenia status during the observation period.

Shiozawa et al (2014) conducted a systematic review of studies evaluating the evidence related to transcutaneous stimulation of the trigeminal or vagus nerve for psychiatric disorders.⁹³ Reviewers also included a fifth study in a data table, although not in their text or a reference list (Hein et al [2013]⁹⁴; previously described). Overall, the studies assessed were limited by small size and poor generalizability.

Impaired Glucose Tolerance

Huang et al (2014) reported on results of a pilot RCT of a tVNS device that provides stimulation to the auricle for the treatment of impaired glucose tolerance.⁹⁵ The trial included 70 patients with impaired glucose tolerance who were randomized to active or sham tVNS, along with 30 controls who received no tVNS treatment. After 12 weeks of treatment, patients who received active tVNS were reported to have significantly lower 2-hour glucose tolerance test results than those who received sham tVNS (7.5 mmol/L vs 8 mmol/L; $p=.004$).

Treatment of Upper-Limb Impairment Due to Stroke

A systematic review by Ramos-Castaneda et al (2022) was introduced above for implanted VNS in stroke and included both implanted and nVNS.⁵⁵ An RCT by Wu et al, which is described below, in addition to 2 other small RCTs were pooled for the analysis comparing nVNS to control in patients with upper limb impairment due to stroke (total $n=64$). Results demonstrated that nVNS did not significantly improve the FMA-UE score vs control (mean difference=2.15; 95% CI, -0.43 to 4.73).

Wu et al (2020) reported results of a randomized, pilot sham-controlled RCT in 21 patients (nVNS=10 and sham nVNS, $n=11$) with upper limb motor function impairment following subacute ischemic stroke.⁹⁶ The mean FMA-UE scores increased by 6.90 with nVNS versus 3.18 points with sham after 15 days of intervention (Difference= -3.72 points; 95% CI, -5.12 to -2.32; $p\leq.001$). The improvement in the mean FMA-UE scores remained significantly higher at both the 4-week (+7.70 vs. +3.36; $p\leq.001$) and the 12-week (+7.40 vs. +4.18; $p=.038$) follow-ups. There was only 1 adverse event noted, which was that 1 patient in the nVNS group developed skin redness at an electrode point of contact.

Fibromyalgia

Kutlu et al (2020) reported results of an RCT that compared a home-based exercise treatment program with or without auricular VNS in 60 female patients in Turkey with fibromyalgia syndrome (auricular VNS $n=30$ and no auricular VNS $n=30$).⁹⁷ The VNS was delivered at Beykoz Public Hospital's Department of Physical Therapy and Rehabilitation in 30-minute sessions on weekdays for 4 weeks. The home-based exercise program consisted of strengthening, stretching, isometric, and posture exercises that targeted the body and upper and lower extremities. When added to exercise, auricular VNS did not significantly improve mean scores on the Fibromyalgia Impact Questionnaire (37.27 vs. 41.93; $p=.378$) or on any 36-Item Short Form Health Survey subscales (e.g., Physical Function: 80. vs. 85.; $p=.167$). An important limitation of this RCT is the lack of a sham control group.

Section Summary: Transcutaneous Vagus Nerve Stimulation for Other Neurologic, Psychiatric, or Metabolic Disorders

tVNS has been investigated in small, randomized trials for several conditions. Some evidence for the efficacy of tVNS for epilepsy comes from a systematic review of 3 small RCTs and an additional RCT, which reported lower seizure rates for active tVNS-treated patients than for sham controls. However, the lack of significant improvement in response rates and quality of life, coupled with important methodological limitations, preclude drawing conclusions about net health outcome. In the study of depression, a small RCT that compared treatment using tVNS with sham stimulation demonstrated some improvements in depression scores with tVNS; however, the lack of comparisons between groups limits conclusions that might be drawn. One RCT of tVNS for treatment of major depressive disorder is registered (NCT02562703) but appears to be unpublished. A sham-controlled pilot randomized trial for impaired glucose

tolerance showed some effect on glucose. A sham-controlled pilot randomized trial for upper limb motor function impairment following subacute ischemic stroke showed some improvement in upper extremity function. A small RCT that compared a home-based exercise treatment program with or without auricular VNS for fibromyalgia syndrome did not find any significant benefits on fibromyalgia or quality of life measures.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Neurology

In 1999, the American Academy of Neurology released a consensus statement on the use of vagus nerve stimulation (VNS) in adults that stated, "VNS is indicated for adults and adolescents over 12 years of age with medically intractable partial seizures who are not candidates for potentially curative surgical resections, such as lesionectomies or mesial temporal lobectomies."⁹⁸ The guidelines were updated in 2013 and reaffirmed in 2022, stating, "VNS may be considered for seizures in children, for LGS [Lennox-Gastaut-syndrome]-associated seizures, and for improving mood in adults with epilepsy (Level C). VNS may be considered to have improved efficacy over time (Level C)."⁹⁹

American Psychiatric Association

Updated in 2010, the American Psychiatric Association guidelines for the treatment of major depressive disorder in adults included the following statement on the use of VNS: "Vagus nerve stimulation (VNS) may be an additional option for individuals who have not responded to at least four adequate trials of antidepressant treatment, including ECT [electroconvulsive therapy]," with a level of evidence III (may be recommended on the basis of individual circumstances)."¹⁰⁰

National Institute for Health and Care Excellence

In 2016, the NICE issued guidance on use of transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552).¹⁰¹ The guidance states: "Current evidence on the safety of transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine raises no major concerns. The evidence on efficacy is limited in quantity and quality." The guidance also comments that further research is needed to clarify whether the procedure is used for treatment or prevention, for cluster headache or migraine, appropriate patient selection, and treatment regimen and suggests that outcome measures should include changes in the number and severity of cluster headache or migraine episodes, medication use, quality of life in the short and long term, side effects, acceptability, and device durability.

In 2018, the NICE published a Medtech innovation briefing on noninvasive VNS for cluster headache (MIB162).¹⁰² The briefing states that the 'intended place in therapy would be as well as standard care, most likely where standard treatments for cluster headache are ineffective, not tolerated or contraindicated' and that key uncertainties around the evidence are that 'people with episodic and chronic cluster headaches respond differently to treatment with gammaCore. The optimal use of gammaCore in the different populations is unclear. The NICE published a Medical technologies guidance [MTG46] on gammaCore for cluster headache in December 2019.¹⁰³ The recommendations state that evidence supports using gammaCore to treat cluster headache and that gammaCore is not effective in everyone with cluster headache.

In 2020, the NICE published an Interventional Procedure Overview on implanted vagus nerve stimulation for treatment-resistant depression (IPG679).¹⁰⁴ The guidance states: "Evidence on the safety of implanted vagus nerve stimulation for treatment-resistant depression raises no major safety concerns, but there are frequent, well-recognized side effects. Evidence on its efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research." The guidance further states that "NICE encourages further research into implanted vagus nerve stimulation for treatment-resistant depression, in the form of randomized controlled trials with a placebo or sham stimulation arm. Studies should report details of patient selection. Outcomes should include validated depression rating scales, patient-reported quality of life, time to onset of effect and duration of effect, and any changes in concurrent treatment."

U.S. Preventive Services Task Force Recommendations

Not applicable.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

Some currently unpublished trials that might influence this review are listed in Table 32.

Table 32. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT03320304 ^a	A Global Prospective, Multi-center, observational Post-market Study to Assess short, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in real-world patients With difficult to Treat depression	500	Recruiting
NCT03887715 ^a	A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)	6800	Recruiting
NCT04935567	Prediction of Vagal Nerve Stimulation Efficacy In Drug-resistant Epilepsy: Prospective Study for Pre-implantation Prediction	120	Not Yet Recruiting
NCT04777500	Applying Transcutaneous Auricular Vagus Nerve Stimulation to Treat Fibromyalgia	60	Mar 2027
NCT04534556	Wireless Nerve Stimulation Device To Enhance Recovery After Stroke	30	(unknown)
NCT04448327	Sex-Dependent Impact of Transcutaneous Vagal Nerve Stimulation on the Stress Response Circuitry and Autonomic Dysregulation in Major Depression	80	Recruiting

NCT04539964 ^a	Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study	243	Active, not recruiting
--------------------------	---	-----	------------------------

NCT: national clinical trial

a Denotes industry-sponsored or cosponsored trial

Regulatory Status:

Table 33 includes updates on the U.S. Food and Drug Administration (FDA) approval and clearance for VNS devices pertinent to this evidence review.

Table 33. FDA Approved or Cleared Vagus Nerve Stimulators

Device Name	Manufacturer	Approved / Cleared	PMA / 510(k)	Product Code(s)	Indications
NeuroCybernetic Prosthesis (NCP®) / VNS Therapy®	LivaNova (Cyberonics, Inc)	1997	P970003	LYJ, MUZ	Indicated or adjunctive treatment of adults and adolescents >12 y of age with medically refractory partial-onset seizures
		2005	P970003/S50		Expanded indication for adjunctive long-term treatment of chronic or recurrent depression for patients ≥18 y of age experiencing a major depressive episode and have not had an adequate response to ≥4 adequate antidepressant treatments
		2017	P970003/S207		Expanded indicated use as adjunctive therapy for seizures in patients ≥4 y of age with partial-onset seizures that are refractory to antiepileptic medications
gammaCore®	ElectroCore	2017/2018	DEN150048 K171306 K173442	PKR, QAK	Indicated for acute treatment of pain associated with episodic cluster and migraine headache in adults using noninvasive VNS on the side of the neck
gammaCore-2®, gammaCore-Sapphire®	ElectroCore	2017/2018/2021	K172270 K180538 K182369 K203456/K211856	PKR	Indicated for: •Adjunctive use for the preventive treatment of cluster headache in adult patients. •The acute treatment of pain associated with episodic cluster headache in adult patients. •The acute treatment of pain associated with migraine headache in adult patients.
Microtransponder® Vivistim® Paired VNS™ system	MicroTransponder, Inc	2021	P210007	QPY	The device is intended to stimulate the vagus nerve during rehabilitation therapy to reduce upper extremity motor deficits and improve motor function in patients with chronic ischemic stroke and moderate to severe arm impairment.
SetPoint System	SetPoint Medical	2025	P240039	SFJ	Indicated for use in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response, or intolerance to one or more biologic or targeted synthetic DMARDs

FDA: U.S. Food and Drug Administration; PMA: premarket approval; VNS: vagus nerve stimulation

Government Regulations

National/Local:

National Coverage Determination (NCD) for Vagus Nerve Stimulation (VNS) (160.18)

Effective Date: 05-04-07; Implementation Date: 07-23-07.

Effective Date of this version: 02/15/2019; Implementation Date: 07/22/2020

Nationally Covered Indications:

Effective for services performed on or after July 1, 1999, VNS is reasonable and necessary for patients with medically refractory partial onset seizures for whom surgery is not recommended or for whom surgery has failed.

Effective for services performed on or after February 15, 2019, the Centers for Medicare & Medicaid Services (CMS) will cover FDA-approved VNS devices for treatment resistant depression (TRD) through Coverage with Evidence Development (CED) when offered in a CMS-approved, double-blind, randomized, placebo-controlled trial with a follow-up duration of at least one year with the possibility of extending the study to a prospective longitudinal study when the CMS-approved, double-blind, randomized placebo-controlled trial has completed enrollment, and there are positive interim findings.

Nationally Non-Covered Indications:

Effective for services performed on or after July 1, 1999, VNS is not reasonable and necessary for all other types of seizure disorders which are medically refractory and for whom surgery is not recommended or for whom surgery has failed.

VNS is non-covered for the treatment of TRD when furnished outside of a CMS-approved CED study.

All other indications of VNS for the treatment of depression are nationally non-covered.

Local:

NA

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Vagus Nerve Blocking for Morbid Obesity (Retired)
 - Percutaneous Electrical Nerve Stimulation (PENS), Percutaneous Neuromodulation Therapy (PNT) and Restorative Neurostimulation Therapy
 - Implantable Peripheral Nerve Stimulation and Peripheral Subcutaneous Field Stimulation Devices for the Treatment of Chronic Pain
 - Obstructive Sleep Apnea and Snoring - Surgical Treatment
-

References

1. Panebianco M, Rigby A, Weston J, et al. Vagus nerve stimulation for partial seizures. *Cochrane Database Syst Rev*. Apr 03 2015(4):Cd002896. PMID 25835947
2. Panebianco M, Rigby A, Marson AG. Vagus nerve stimulation for focal seizures. *Cochrane Database Syst Rev*. Jul 14 2022; 7(7): CD002896. PMID 35833911
3. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. *J Neurosurg*. Dec 2011;115(6):1248-1255. PMID 21838505
4. Ben-Menachem E, Hellstrom K, Waldton C, et al. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. *Neurology*. Apr 12 1999;52(6):1265-1267. PMID 10214754
5. Parker AP, Polkey CE, Binnie CD, et al. Vagal nerve stimulation in epileptic encephalopathies. *Pediatrics*. Apr 1999;103(4 Pt 1):778-782. PMID 10103302
6. Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group. *Neurology*. Apr 22 1999;52(7):1510-1512. PMID 10227649
7. DeGiorgio CM, Schachter SC, Handforth A, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. *Epilepsia*. Sep 2000;41(9):1195-1200. PMID 10999559
8. Chavel SM, Westerveld M, Spencer S. Long-term outcome of vagus nerve stimulation for refractory partial epilepsy. *Epilepsy Behav*. Jun 2003;4(3):302-309. PMID 12791333
9. Vonck K, Boon P, D'Have M, et al. Long-term results of vagus nerve stimulation in refractory epilepsy. *Seizure*. Sep 1999;8(6):328-334. PMID 10512772
10. Vonck K, Thadani V, Gilbert K, et al. Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. *J Clin Neurophysiol*. Jul-Aug 2004;21(4):283-289. PMID 15509917
11. Majoie HJ, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. *J Clin Neurophysiol*. Sep 2001;18(5):419-428. PMID 11709647
12. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one-year outcomes. *Biol Psychiatry*. Feb 15 2002;51(4):280-287. PMID 11958778
13. Huf RL, Mamelak A, Kneedy-Cayem K. Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. *Epilepsy Behav*. May 2005;6(3):417-423. PMID 15820352
14. Kang HC, Hwang YS, Kim DS, et al. Vagus nerve stimulation in pediatric intractable epilepsy: a Korean bicentric study. *Acta Neurochir Suppl*. 2006;99:93-96. PMID 17370772
15. Ardesch JJ, Buschman HP, Wagener-Schimmel LJ, et al. Vagus nerve stimulation for medically refractory epilepsy: a long-term follow-up study. *Seizure*. Oct 2007;16(7):579-585. PMID 17543546
16. Michael JE, Wegener K, Barnes DW. Vagus nerve stimulation for intractable seizures: one year follow-up. *J Neurosci Nurs*. Dec 1993;25(6):362-366. PMID 8106830
17. Ben-Menachem E, Manon-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. *Epilepsia*. May-Jun 1994;35(3):616-626. PMID 8026408

18. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. *Neurology*. Jul 1998;51(1):48-55. PMID 9674777
19. Klinkenberg S, Aalbers MW, Vles JS, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. *Dev Med Child Neurol*. Sep 2012;54(9):855-861. PMID 22540141
20. Ryvlin P, Gilliam FG, Nguyen DK, et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. *Epilepsia*. Jun 2014;55(6):893-900.
21. Englot DJ, Rolston JD, Wright CW, et al. Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. *Neurosurgery*. Sep 2016;79(3):345-353. PMID 26645965
22. Garcia-Navarrete E, Torres CV, Gallego I et al. Long-term results of vagal nerve stimulation for adults with medication-resistant epilepsy who have been on unchanged antiepileptic medication. *Seizure* 2013; 22(1):9-13.
23. Hornig GW, Murphy JV, Schallert G, et al. Left vagus nerve stimulation in children with refractory epilepsy: an update. *South Med J*. May 1997;90(5):484-488. PMID 9160063
24. Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. *J Pediatr* 1999; 134(5):563-6.
25. Patwardhan RV, Stong B, Bebin EM et al. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. *Neurosurgery* 2000; 47(6):1353-8.
26. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. *Epilepsia*. Sep 2001;42(9):1148-1152. PMID 11580762
27. You SJ, Kang HC, Kim HD, et al. Vagus nerve stimulation in intractable childhood epilepsy: a Korean multicenter experience. *J Korean Med Sci*. Jun 2007;22(3):442-445. PMID 17596651
28. Cukiert A, Cukiert CM, Burattini JA, et al. A prospective long-term study on the outcome after vagus nerve stimulation at maximally tolerated current intensity in a cohort of children with refractory secondary generalized epilepsy. *Neuromodulation*. Nov 2013;16(6):551-556. PMID 23738578
29. Healy S, Lang J, Te Water Naude J et al. Vagal nerve stimulation in children under 12 years old with medically intractable epilepsy. *Childs Nerv Syst*. Nov 2013; 29(11):2095-9. PMID 23681311
30. Terra VC, Furlanetti LL, Nunes AA, et al. Vagus nerve stimulation in pediatric patients: Is it really worthwhile? *Epilepsy Behav*. Feb 2014;31:329-333. PMID 24210463
31. Yu C, Ramgopal S, Libenson M, et al. Outcomes of vagal nerve stimulation in a pediatric population: A single center experience. *Seizure*. Feb 2014;23(2):105-11. PMID 24309238
32. Maleknia P, McWilliams TD, Barkley A, et al. Postoperative seizure freedom after vagus nerve stimulator placement in children 6 years of age and younger. *J Neurosurg Pediatr*. Apr 01 2023; 31(4): 329-332. PMID 36670534
33. Daban C, Martinez-Aran A, Cruz N, et al. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. *J Affect Disord*. Sep 2008;110(1-2):1-15. PMID 18374988
34. Rush AJ, Marangell LB, Sackheim HA et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. *Biol Psychiatry*. Sep 01 2005; 58(5):347-54. PMID 16139580

35. Food and Drug Administration. Summary of Safety and Effectiveness Data: VNS Therapy™ System. 2005;
https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s050b.pdf Accessed 3/17/26
36. Martin JL, Martin-Sanchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. *Eur Psychiatry*. Apr 2012;27(3):147-155. PMID 22137776
37. Berry SM, Broglio K, Bunker M et al. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. *Med Devices (Auckl)*. 2013; 6:17-35. PMID 23482508
38. Bajbouj M, Merkl A, Schlaepfer TE et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. *J Clin Psychopharmacol*. Jun 2010; 30(3):273-81. PMID 20473062
39. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. *Brain Stimul*. Jul 2013;6(4):631-640. PMID 23122916
40. Bottomley JM, LeReun C, Diamantopoulos A, et al. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: A systematic review and meta-analysis. *Compr Psychiatry*. Dec 12 2019; 98: 152156. PMID 31978785
41. Conway CR, Aaronson ST, Sackeim HA, et al. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. *Brain Stimul*. 2025; 18(3): 676-689. PMID 39706521
42. Rush AJ, Conway CR, Aaronson ST, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. *Brain Stimul*. 2025; 18(3): 690-700. PMID 39701918
43. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. *Biol Psychiatry*. Sep 01 2005;58(5):364-373. PMID 16139582
44. De Ferrari GM, Crijns HJ, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. *Eur Heart J*. Apr 2011;32(7):847-855. PMID 21030409
45. Aaronson ST, Sears P, Ruvuna F, et al. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. *Am J Psychiatry*. Jul 01 2017; 174(7): 640-648. PMID 28359201
46. McAllister-Williams RH, Sousa S, Kumar A, et al. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. *Int J Bipolar Disord*. May 02 2020; 8(1): 13. PMID 32358769
47. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. *Biol Psychiatry*. Feb 15 2000;47(4):276-286. PMID 10686262
48. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology*. Nov 2001;25(5):713-728. PMID 11682255
49. Marangell LB, Suppes T, Zboyan HA et al. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. *J Clin Psychiatry*. Feb 2008; 69(2):183-9. PMID 18211128

50. Tisi G, Franzini A, Messina G, et al. Vagus nerve stimulation therapy in treatment-resistant depression: a series report. *Psychiatry Clin Neurosci*. Aug 2014;68(8):606-611. PMID 25215365
51. Sant'Anna LB, Couceiro SLM, Ferreira EA, et al. Vagal Neuromodulation in Chronic Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. *Front Cardiovasc Med*. 2021; 8: 766676. PMID 34901227
52. Premchand RK, Sharma K, Mittal S, et al. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. *J Card Fail*. Nov 2014;20(11):808-816. PMID 25187002
53. Nearing BD, Libbus I, Carlson GM, et al. Chronic vagus nerve stimulation is associated with multi-year improvement in intrinsic heart rate recovery and left ventricular ejection fraction in ANTHEM-HF. *Clin Auton Res*. Jun 2021; 31(3): 453-462. PMID 33590355
54. Kumar HU, Nearing BD, Mittal S, et al. Autonomic regulation therapy in chronic heart failure with preserved/mildly reduced ejection fraction: ANTHEM-HFpEF study results. *Int J Cardiol*. Jun 15 2023; 381: 37-44. PMID 36934987
55. Ramos-Castaneda JA, Barreto-Cortes CF, Losada-Floriano D, et al. Efficacy and Safety of Vagus Nerve Stimulation on Upper Limb Motor Recovery After Stroke. A Systematic Review and Meta-Analysis. *Front Neurol*. 2022; 13: 889953. PMID 35847207
56. Dawson J, Pierce D, Dixit A, et al. Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. *Stroke*. Jan 2016;47(1):143-150. PMID 26645257
57. Dawson J, Liu CY, Francisco GE, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. *Lancet*. Apr 24 2021; 397(10284): 1545-1553. PMID 33894832
58. Kimberley TJ, Pierce D, Prudente CN, et al. Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Chronic Stroke. *Stroke*. Nov 2018;49(11). PMID 30355189
59. Lange G, Janal MN, Maniker A, et al. Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial. *Pain Med*. Sep 2011;12(9):1406-1413. PMID 21812908
60. Kimberley TJ, Cramer SC, Wolf SL, Liu C, Gochyyev P, Dawson J; VNS-REHAB Trial Group. Long-Term Outcomes of Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation After Stroke. *Stroke*. 2025 Aug;56(8):2255-2265. doi: 10.1161/STROKEAHA.124.050479. Epub 2025 May 7. PMID: 40329913.
61. Engineer CT, Hays SA, Kilgard MP. Vagus nerve stimulation as a potential adjuvant to behavioral therapy for autism and other neurodevelopmental disorders. *J Neurodev Disord*. Jul 2017;9:20. PMID 28690686
62. SetPoint Medical Receives FDA's IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing Remitting MS [SetPoint Medical Receives FDA's IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis](#) accessed 3/17/26
63. Jokic M, Lee C, Holubowich C, et al. Noninvasive Vagus Nerve Stimulation for Cluster Headache and Migraine: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2025; 25(2): 1-177. PMID 40496978
64. Gaul C, Diener HC, Silver N, et al. Non-invasive vagus nerve stimulation for PREvention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. *Cephalalgia*. May 2016;36(6):534-46. PMID 26391457

65. Gaul, C, Magis, D, Liebler, E, et al. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. *J Headache Pain*. Dec 2017;18(1):22 PMID 28197844
66. Tfelt-Hansen, P, Pascual, J, Ramadan, Net al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. *Cephalalgia*. Jan 2012;32(1):6-38 PMID 22384463
67. Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-invasive vagus nerve stimulation for the Acute Treatment of Cluster Headache: findings from the randomized, double-blind, sham-controlled ACT1 Study. *Headache*. Sep 2016;56(8):1317-1332. PMID 27593728
68. Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. *Cephalalgia*. Apr 2018;8(5):1317-32 PMID 29231763
69. de Coo IF, Marin JC, Silberstein SD, et al. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. *Cephalalgia*. Jul 2019;39(8):967-77. PMID 31246132
70. Tassorelli, C, Grazzi, L, de Tommaso, M et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. *Neurology*. Jul 24 2018;9(4):e364-e373. PMID 29907608
71. Grazzi, L, Tassorelli, C, de Tommaso, M et al. Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham controlled, double-blind PRESTO trial.. *J Headache Pain*. Oct 19 2018;19(1):98. PMID 30340460
72. Martelletti, P, Barbanti, P, Grazzi, L et al. Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. *J Headache Pain*. Nov 01 2018;19(1):101. PMID 30382909
73. Trimboli, M, Al-Kaisy, A, Andreou, A, et al. Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience. *Cephalalgia*. Jun 2018;38(7):1276-85 PMID 28899205
74. Silberstein, SD, Calhoun, AH, Lipton, RB et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. *Neurology*. Aug 02 2016;87(5):529-38. PMID 27412146
75. Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, doubleblind, randomised, sham-controlled PREMIUM trial. *Cephalalgia*, Oct 2019;39(12):1475-87. PMID 31522546
76. Najib U, Smith T, Hindiyeh N, et al. Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. *Cephalalgia*. Jun 2022; 42(7): 560-569. PMID 35001643Grazzi L, Egeo G, Calhoun AH, et al. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. *J Headache Pain*. Dec 2016;17(1):91 PMID 27699586
77. Grazzi L, Egeo G, Calhoun AH, et al. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. *J Headache Pain*. Dec 2016; 17(1): 91. PMID 27699586
78. Kiefe TM, Pintea B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. *J Headache Pain*. 2015;16:101 PMID 26631234

79. Saylor A, Patrick L, Reddy CG, Gandhi R. Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation for Chronic Stroke: Real-World Implementation and Outcomes. *Arch Rehabil Res Clin Transl*. 2026 Jan 2;8(1):100580. doi: 10.1016/j.arrct.2025.100580. PMID: 41834814; PMCID: PMC12988562.
80. Khan I, Shakir M, Vijayanarasimhan V, Lodhi BA, Parker JJ, Miller KJ, Khan M, Grewal SS, Ali R. Implantable Vagus Nerve Stimulator-Paired Neurorehabilitation for Upper Limb Function After Ischemic Stroke: Evidence From a Systematic Review and Meta-Analysis With Best Practice Recommendations. *Neurosurgery*. 2025 Dec 1;97(6):1242-1256. doi: 10.1227/neu.0000000000003545. Epub 2025 Jun 3. PMID: 40459273.
81. Johnson TM, Michaud K, England BR. Measures of rheumatoid arthritis disease activity. *Arthritis Care Res*. 2020;72(suppl 10):4-26. doi:10.1002/acr.24336.
82. Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. *Rheumatology (Oxford)*. Jun 2016; 55(6): 1031-41. PMID 26929445
83. Genovese MC, Gaylis NB, Sikes D, et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. *Lancet Rheumatol*. Sep 2020; 2(9): e527-e538. PMID 38273617
84. Peterson D, Van Poppel M, Boling W, et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. *Bioelectron Med*. Mar 13 2024; 10(1): 8. PMID 38475923
85. SetPoint Medical. SetPoint System: Surgeon Instructions for Use. https://setpointmedical.com/wp-content/uploads/DWG_65154_Surgeon_IFUv2.pdf. Accessed October 31, 2025.
86. Aihua L, Lu S, Liping L, et al. A controlled trial of transcutaneous vagus nerve stimulation for the treatment of pharmacoresistant epilepsy. *Epilepsy Behav*. Oct 2014;39:105-110. PMID 25240121
87. Bauer S, Baier H, Baumgartner C, et al. Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02). *Brain Stimul*. May-Jun 2016; 9(3): 356-363. PMID 27033012
88. Rong P, Liu A, Zhang J, et al. Transcutaneous vagus nerve stimulation for refractory epilepsy: a randomized controlled trial. *Clin Sci (Lond)*. Apr 01 2014. PMID 24684603
89. Wu K, Wang Z, Zhang Y, et al. Transcutaneous vagus nerve stimulation for the treatment of drug-resistant epilepsy: a meta-analysis and systematic review. *ANZ J Surg*. Apr 2020; 90(4): 467-471. PMID 32052569
90. Yang H, Shi W, Fan J, et al. Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial. *Neurotherapeutics*. Apr 2023; 20(3): 870-880. PMID 36995682
91. Shi J, Lu D, Wei P, et al. Comparative Efficacy of Neuromodulatory Strategies for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis. *World Neurosurg*. Jan 2025; 193: 373-396. PMID 39321920
92. Hasan A, Wolff-Menzler C, Pfeiffer S, et al. Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. *Eur Arch Psychiatry Clin Neurosci*. Oct 2015;265(7):589-600. PMID 26210303
93. Shiozawa P, Silva ME, Carvalho TC, et al. Transcutaneous vagus and trigeminal nerve stimulation for neuropsychiatric disorders: a systematic review. *Arq Neuropsiquiatr*. Jul 2014;72(7):542-547. PMID 25054988

94. Hein E, Nowak M, Kiess O, et al. Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. *J Neural Transm (Vienna)*. May 2013; 120(5): 821-7. PMID 23117749
95. Huang F, Dong J, Kong J, et al. Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study. *BMC Complement Altern Med*. 2014;14:203. PMID 24968966
96. Wu D, Ma J, Zhang L, et al. Effect and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Recovery of Upper Limb Motor Function in Subacute Ischemic Stroke Patients: A Randomized Pilot Study. *Neural Plast*. 2020; 2020: 8841752. PMID 32802039
97. Kutlu N, Ozden AV, Alptekin HK, et al. The Impact of Auricular Vagus Nerve Stimulation on Pain and Life Quality in Patients with Fibromyalgia Syndrome. *Biomed Res Int*. 2020; 2020: 8656218. PMID 32190684
98. Fisher RS, Handforth A. Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. Sep 11 1999;53(4):666-669. PMID 10489023
99. Morris GL, 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. Oct 15 2013;81(16):1453-1459. PMID 23986299
100. American Psychiatric Association, Work Group on Major Depressive Disorder, Gelenberg AJ, et al. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Third Edition. 2010; 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf Accessed 3/17/26.
101. National Institute for Health and Care Excellence. Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552). 2016; <https://www.nice.org.uk/guidance/ipg552> Accessed 3/17/26
102. National Institute for Health and Care Excellence. gammaCore for cluster headache (MIB162). 2018. <https://www.nice.org.uk/advice/mib162> Accessed 3/9/26
103. National Institute for Health and Care Excellence. Medical technologies guidance [MTG46]: gammaCore for cluster headache. December 2019. <https://www.nice.org.uk/guidance/MTG46> Accessed 3/17/26
104. National Institute for Health and Care Excellence. Implanted vagus nerve stimulation for treatment-resistant depression - Interventional Procedures Guidance (IPG679). 2020; <https://www.nice.org.uk/guidance/ipg679/chapter/1-Recommendations> Accessed 3/17/26
105. National Coverage Determination (NCD) for VAGUS Nerve Stimulation (VNS) (160.18). 2020 <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=230>.
106. Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Bolland E, Lux L, Weber RP, Randolph C, Bann C, Coker-Schwimmer E, Viswanathan M, Lohr KN. Definition of Treatment-Resistant Depression in the Medicare Population [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Feb 9. PMID: 30260611.
107. Centers for Medicare & Medicaid Services. Coverage with Evidence Development for Vagus Nerve Stimulation for Treatment Resistant Depression. 2024. <https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/VNS>. Accessed 3/9/26
108. Conway CR, Olin B, Aaronson ST, et al. A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A

novel design for a novel treatment. Contemp Clin Trials. Aug 2020; 95: 106066. PMID 32569757

109. SetPoint Medical FDA [SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of MS](#) accessed 3/17/26
110. RESET-RA Study [Home - SetPoint RESET-RA](#) accessed 3/17/26

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through March 2026, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
6/15/05	6/15/05	5/23/05	Routine maintenance (depression into separate policy in 2006)
3/16/06	3/16/06	3/17/06	Joint policy established
5/1/07	3/1/07	5/1/07	Routine maintenance
7/1/08	5/17/08	5/18/08	Routine maintenance
11/1/08	8/19/08	10/30/08	VNS for Seizures and Depressions combined
3/1/10	12/8/09	12/8/09	Routine maintenance
5/1/11	2/15/11	3/3/11	Routine maintenance; CPT code updates, added procedure codes 64568, 64569 and 64570. Deleted CPT code 64573
7/1/12	4/10/12	5/22/12	Routine maintenance; 2012 code update - revision to nomenclature for codes 95970, 95974 and 95975.
7/1/13	4/16/13	4/22/13	Routine maintenance; updated description and rationale to mirror BCBSA's policy.
11/1/14	8/19/14	8/28/14	Routine maintenance - Added nonimplantable VNS, tinnitus and TBI to list of exclusions. Codes L8680-L8689 added to the policy
7/1/16	4/19/16	4/19/16	Routine maintenance
7/1/17	4/18/17	4/18/17	Routine maintenance
7/1/18	4/17/18	4/17/18	Routine maintenance. Inclusions and exclusions more aligned with BCBSA. Specified that cluster headaches and migraines; autism and schizophrenia are excluded. E0770 added as E/I.

7/1/19	4/16/19		Routine maintenance Deleted codes 95974 and 95975; added new codes 95976 and 95977 Updated Regulatory status to reflect FDA approval to expand indications for the gammaCore to include the acute treatment of pain associated with migraine headaches in adults. Added Medicare coverage information for treatment-resistant depression.
7/1/20	4/14/20		Routine maintenance
7/1/21	4/20/21		Routine maintenance
9/1/21	6/15/21		Code update, added K1020
7/1/22	4/19/22		Routine maintenance Ref 47, 49, 51 added
7/1/23	4/18/23		Routine maintenance (jf) Vendor Managed: Northwood code E0770 Literature review: Vivistim® added code from the BCBSA C1827as E/I. Updated Regulatory status to reflect FDA approval to expand indications for the Vivistim System. Added line under section summary under Upper limb impairment due to stroke Longer-term follow-up studies are needed to evaluate long-term efficacy and safety. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome
7/1/24	4/16/24		Routine maintenance (jf) Vendor Managed: (BCNA MAPPO HMO PPO* Turning Point they use Vagus Nerve Stimulation (VNS) NCD policy on their website 160.18 ○ L8680,L8681, L8682, L8683,L8685, L8686, L8687,L8688, L8689. Northwood: E0770

			2024 CPT code update : Add code(s) 61889, 61891 and 61892 as payable. 2024 Annual HCPCS update Temporary HCPCS code K1020 is being deleted. E0735 added to policy as E/I. Ref: Added 32,52 -Added asterisk * and policy guidelines to support our Inclusionary criteria. ○ *Medically refractory seizures are defined as seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels of antiepileptic drugs because of intolerable adverse events of these drugs.
7/1/25			Routine maintenance (jf) Vendor Managed: NA Northwood: E0770 Email on 4/15/25 indicated Turning Point does not managed these codes (L8680,L8681, L8682, L8683,L8685, L8686, L8687,L8688, L8689) for vagus nerve stimulators. TP is managing these codes related to spinal cord stimulators. • Code Update CPT Early Release T Code Update. Add the following codes as E/I 0908T, 0909T,0910T,0911T,0912 T • SetPoint System added under regulatory FDA section as FDA Breakthrough Device Designation • Edits exclusions: added Rheumatoid arthritis and Integrated vagus nerve neurostimulation systems are considered experimental/investigational for all indications.

			• Edit to the MPS removed safety and effectiveness • Individuals replaced patients • Removal of L8684 from policy as it does not fit this policy • Added Ref: 95,96,97 Added note: *Note: The implantation, replacement, removal, analysis and programming of integrated vagus nerve neurostimulation systems is represented by codes 0809T, 0909T, 0910T, 0911T, and 0912T. Currently there are no FDA approved integrated neurostimulation systems. Post JUMP: Added description difference between the implantable, transcutaneous, and integrated systems.
7/1/26			Routine maintenance (jf/mk) Vendor Managed: NA Northwood: E0770 Ref added: 41,42,60,83,84,79,80,81,82,83,84,85, 91,113 • Formatting changes made: ○ Sections rearranged for better flow ○ Added Description and Background separated ○ MPS edited ○ Notes added in code section Literature Review: Vivistm

Next Review Date: 2nd Qtr, 2027

Joint BCBSM/BCN Medical Policy History for VNS for Seizures

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
2/13/02	2/13/02	2/13/02	Joint policy established
5/17/04	5/17/04	6/22/04	Addition of exclusion of depression, updated references

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: VAGUS NERVE STIMULATION

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Covered; criteria apply.
BCNA (Medicare Advantage)	See Government Regulations section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.